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Benzodiazepines belong to the most prescribed drugs in Western countries. In the 
Netherlands they are registered for the symptomatic treatment of pathological anxiety, 
tension and severe insomnia. Their use is indicated, with some reserve, for short-term 
treatment (two weeks or four weeks of intermittent use) of severe insomnia with poor day-
time functioning, and for the treatment of pathological anxiety and tension for a period no 
longer than two months. Nonetheless, in none of the Dutch guidelines for the treatment of 
mental disorders benzodiazepines are considered as a first treatment option for any 
disorder.-5
In 005 approximately 0.9 million prescriptions for benzodiazepines were issued in 
the Netherlands. In that year the number of benzodiazepine users was estimated at .9 
million, which corresponds with a prevalence rate in one year of about .7% (of the total 
Dutch population of . million people). 
In spite of the above mentioned guidelines and the lack of evidence concerning the 
effectiveness of benzodiazepines with prolonged treatment,7 in actual practice a 
considerable number of patients are using these drugs long-term. Reported prevalence 
rates of long-term use vary considerably as a consequence of differences in definition 
and observation period. Nonetheless, in 998 7% of all benzodiazepine users in the 
Netherlands could be considered long-term users, ranging from at least three months to 
many years of daily or intermittent use (prevalence rate 4.% - 5.% a year, based on a 
total population of 5.4 million people with health insurance).8 This group received at least 
 prescriptions a year in an amount of  defined daily dosages (DDD*) according to 
therapeutic dosages of the World Health Organisation (WHO), which was actually lower 
than the current recommended dosage. In 9% of the long-term users, the benzodiazepines 
were indicated for anxiolytic use, in % for hypnotic use, and the remaining 9% received 
prescriptions for both purposes.8 The demographic characteristics of these long-term 
benzodiazepine users show that half to two-thirds are female and half are aged 5 or 
over.,8-0 Most long-term users (89%) receive their benzodiazepine prescription from their 
general practitioner.8
In this thesis long-term use is defined as use for at least three months: ) this time 
window corresponds well with the guidelines for the maximum treatment duration and 
) research has shown that there is a significant decrease in spontaneous discontinuation 
of benzodiazepine use after this period., 
* Defined Daily Dosage [standaarddagdosering] (DDD) is an international unit of pharmaceutical utilisation. It is 
an approximation of the amount of active substance that an adult with a bodyweight of 70 kg receives per day. 
For example, the DDD for diazepam is 0 mg. DDDs are established by the Nordic Council on Medicines and the 
World Health Organization Drug Utilisation Research Group.48
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Long-term use of benzodiazepines is not free of risks, particularly not in the elderly: 
benzodiazepines can cause cognitive disturbance (effects on memory), have a negative 
influence on driving behaviour and increase the risk of falling and consequently of hip 
fractures (for an overview, see e.g.). 
Another important issue in the long-term use of benzodiazepines is their potential for 
causing dependence. Not long after their discovery in the 90’s, there were reports of 
benzodiazepines causing physical dependence after long-term high dose treatment. Not 
long thereafter physical dependence in normal-dose benzodiazepine usage was reported.4,5 
Research has shown that benzodiazepines have all the characteristics of drugs of 
dependence, including tolerance, escalation of dosage, continued use despite efforts to 
stop and knowledge of adverse effects, several behavioural features, and a withdrawal 
syndrome (table ). A substantial number of general practice patients using normal dosages 
of benzodiazepines are dependent on these drugs, i.e. 40% according to DSM-III-R-criteria, 
and 5% when applying ICD-0 criteria.9 Long-term users make up the largest group of 
benzodiazepine-dependent patients.
Table 1 Criteria for benzodiazepine dependence according to DSM-IV17 and ICD-1018 criteria
Diagnostic and Statistical Manual of Mental Disorders, 
4th edition (DSM-IV)
International Classification of Diseases,
10th edition (ICD-10)
Three (or more) of the following, occurring any time in the 
same 12-month period:
Three or more of the following have been present together 
at some time during the previous year:
• Tolerance • Tolerance
• Withdrawal • Physiological withdrawal state when substance use has 
ceased or been reduced
• The substance is often taken in larger amounts or over a 
longer period than intended
• -
• There is a persistent desire or unsuccessful efforts to cut 
down or control substance use
• Difficulties in controlling substance-taking behaviour in 
terms of its onset, termination, or levels of use
• A great deal of time is spent in activities necessary to 
obtain the substance, use the substance, or recover from 
its effects
• Progressive neglect of alternative pleasures or interests 
because of psychoactive substance use, increased amount 
of time necessary to obtain or take the substance or to 
recover from its effects
• Important social, occupational, or recreational activities 
are given up or reduced because of substance use
• -
• The substance use is continued despite knowledge of 
having a persistent physical or psychological problem 
that is likely to have been caused or exacerbated by the 
substance
• Persisting with substance use despite clear evidence of 
overtly harmful consequences
• - • Craving: a strong desire or sense of compulsion to take 
the substance
In addiction literature craving is regarded as an important aspect of dependence. The 
International Classification of Diseases, 0th edition (ICD-0) has listed craving, simply 
defined as a ‘strong desire or compulsion’ to use a drug, as one of the dependence criteria.8 
Although craving is likely to be experienced by most (if not all) individuals with substance 
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dependence,7 there is still little consensus about its definition and theory, its causes and 
consequences, and its measurement.0-
Current psychological craving models (phenomenological, conditioning and cognitive) 
are mainly based on models of addiction. Neither provides a sufficient explanation for the 
nature of craving and the conditions under which it might occur. Moreover, some have not 
been empirically tested yet. Psychobiological models of craving assume a neurobiological 
basis for conditioning processes. Involvement of neurotransmitter systems, such as the 
dopaminergic system, has been reported in drug craving. These models are predominantly 
based on animal studies and have often not been tested in humans. For an overview of 
contemporary craving models, see e.g4-8.
Nevertheless, from a psychological perspective, there is general agreement that craving 
is a subjective state in humans associated with drug dependence and that it has multiple 
determinants. Craving has been proposed as a factor in maintaining continued use or 
relapse in substance-dependent subjects, although, some studies have shown that craving 
not always precedes drug use and does not always result in drug use (e.g.9-). Dependent 
subjects may even continue to experience craving years after their last drug use (e.g.-5) 
and regular substance users describe experiencing craving even when they are not 
attempting to abstain from drug use (e.g.,7).
As mentioned above there is no standardised methodology for measuring craving, nor 
is there a general agreement about how to develop psychometrically sound indices. 
Physiological measures, e.g. heart rate, skin temperature and skin conductance, have also 
been used as an indicator of craving. However, the relationship between these measures 
and self-reported craving is ambiguous.4 In the past few years, craving researchers have 
also used neuroimaging methods (e.g. positron emission tomography (PET) and functional 
magnetic resonance imaging (fMRI)) to analyse the involvement of certain brain structures 
(e.g. certain frontal cortical areas and limbic structures) in the behavioural, cognitive and 
emotional processes that are assumed to be at the core of addiction. Several studies have 
found a consistent relationship between activation of certain brain areas and self-reported 
craving (for a review see e.g.,8,9). These methods, however, are beyond the scope of this 
thesis. 
As craving is generally regarded as a subjective phenomenon, its assessment is often 
based on self-reports. Most craving measures today use gradual or continuous scales, 
varying from visual analogue scales (e.g.40), single-item Likert-type scales (e.g.4) to multi-
item multidimensional questionnaires (e.g.,7,4). There are only few instruments of which 
the psychometric properties have been addressed and have proven to be promising. 
The Questionnaire on Smoking Urges (QSU) and the Cocaine Craving Questionnaire 
(CCQ),7 are self-report instruments directed at four, respectively, five distinct conceptual 
areas relevant to craving, in order to cover current craving theories as widely as possible: 
desire to use, anticipation of positive outcome, relief of withdrawal or (withdrawal-
associated) negative affect, intention to use, and lack of control. The data obtained with 
the QSU and CCQ have shown multidimensional features of craving. These questionnaires 
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have provided a model for the development of many other questionnaires, among which 
the Benzodiazepine Craving Questionnaire (BCQ), described in this thesis.
Benzodiazepine craving research is scarce. In the late 980’s, Van and Zitman4 called 
for attention to the concept of craving (defined as ‘the urge for renewed use’) as part of 
benzodiazepine dependence. In an explorative study among 7 female benzodiazepine 
users taking part in a so-called self-help group, they found that  females met their 
criteria for craving (their questionnaire was not tested on psychometric properties, however) 
and  females made verbatim reports of yearning for their benzodiazepine. Since then 
there have been few studies addressing the concept of craving in the context of 
benzodiazepine use and dependence, and they yielded contradicting results. In a study by 
Lucki, Volpicelli and Schweizer,44 patients who had discontinued their benzodiazepine use, 
including the long-term users, expressed little or no craving for the drug. Patients completed 
a craving questionnaire that asked about the intensity and frequency of their desire or urge 
for benzodiazepines during the previous week. Contrasting findings were reported by 
Linden, Bar and Geiselmann,45 who argued that the refusal of about two thirds of their 
general practice patients, with long-term low-dose benzodiazepine dependence, to accept 
a short drug-free intermission, provided evidence for drug-seeking or craving behaviour. 
Apparently, these authors regarded craving to be the equivalent of drug insistence. Kan 
and colleagues9 suggested that about 84% of their general practice patients using 
benzodiazepines experienced craving, as operationalised by four items of the SCAN 
(Schedules for Clinical Assessment in Neuropsychiatry). The SCAN items were adapted for 
benzodiazepines, but the validity of this approach to measure craving has not been tested. 
THESIS OUTLINE
The main purpose of this study is to initiate benzodiazepine craving research in order to 
fill the gap in the craving research area and to advance our knowledge about benzodiazepine 
craving. 
Chapter 2 describes the development and psychometrical evaluation of the Benzodiazepine 
Craving Questionnaire (BCQ) in a sample of 9 long-term general practice benzodiazepine 
users, participating in the Benzoredux project. The construction of the BCQ is described 
and Rasch analysis is carried out to assess its scalability. Subsequently, the reliability of 
the BCQ is evaluated in terms of subject and item discriminability. In order to determine 
the validity of the BCQ, construct and discriminative validity are assessed. In light of the 
results, the utility of the BCQ is discussed.
Chapter 3 characterises long-term general practice benzodiazepine users (n = ) and 
former long-term benzodiazepine users (n = 80) reporting craving for benzodiazepines. 
Furthermore, it describes which subject-related variables, based on associations frequently 
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found with craving in other substances, are associated with benzodiazepine craving. The 
length to which these results support and challenge existing craving theories and other 
empirical findings is discussed.
Chapter 4 addresses the course of benzodiazepine craving, over a -month follow-up 
period by means of four repeated measurements of benzodiazepine craving, in a sample of 
7 patients. We assess whether the self-reported craving severity, as measured with the 
BCQ, differs among several assessments in time and whether the overall experienced 
craving differs between patients who have quit their benzodiazepine use, patients who 
continue using benzodiazepines, and patients with intermittent use patterns. In addition, 
we examine whether the way in which patients have attempted to discontinue their 
benzodiazepine use (of their own accord or with additional tapering off guided by their 
general practitioner, with or without group cognitive-behavioural therapy) influences their 
self-reported craving over time. 
Chapter 5 addresses the issue of craving conceptualisation. A broad conceptualisation 
of benzodiazepine craving, as represented by the BCQ, is compared to a narrow 
conceptualisation, as represented by the Benzodiazepine Desire Scale (BDS). The BDS is 
composed of three single-item Likert-type scales assessing frequency, global and peak 
intensity of the desire for benzodiazepines. Together with other (benzodiazepine 
dependence related) variables, they are analysed by means of factor analysis. Implications 
of our findings are discussed. 
Chapter 6 examines the predictive value of craving on benzodiazepine relapse after 
discontinuation of long-term benzodiazepine use. Predictors of benzodiazepine relapse 
found in other studies, benzodiazepine use characteristics, and the variables measured at 
the baseline assessment, are analysed in long-term benzodiazepine users who have success-
fully quit their usage by themselves after a minimal intervention (n = 79), respectively, 
after a supervised benzodiazepine tapering off programme in general practice (n = 45).
Chapter 7 presents a general discussion, in which the major conclusions are summed up, 
limitations of the study are discussed, and adaptations and ideas for further research are 
suggested in order to further substantiate the psychometric properties of the BCQ. The 
thesis is concluded by a summary.
All data were collected within the Benzoredux project. The general structure of this project 
is briefly presented below in box .
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Box 1 Design of the Benzoredux project
The Benzoredux project was carried out with ethical approval of the Radboud University Nijmegen Medical Centre 
between 1998 and 2001. It was funded by the Dutch Health Care Insurance Council (College voor Zorgverzekeringen, 
project OG97-015).
The Benzoredux project was designed to evaluate a stepped care approach to reduce long-term benzodiazepine use 
in general practice. Long-term benzodiazepine use was defined as use for at least three months with a prescribed 
amount sufficient for at least 60 days of consumption in accordance with the recommended dosage. In the first phase 
of the study, a so-called ‘minimal’ intervention strategy was evaluated. Patients received a letter from their general 
practitioner with the advice to gradually cut down their use of benzodiazepines by themselves and, if possible, to stop 
using them altogether. Patients who did not discontinue their use of benzodiazepines after this intervention were 
encouraged to participate in a more intensive consecutive phase of the study: a randomised controlled trial consisting 
of a tapering off programme with or without simultaneous group cognitive-behavioural therapy. 
At the evaluation consultation three months after the minimal intervention, patients were asked to give their 
informed consent for the study, after which the baseline assessment was carried out. The baseline assessment took 
place approximately three months after the start of the minimal intervention. Three months after the start of the 
second intervention, patients received a short-term outcome assessment, followed by three follow-up assessments, 
6, 12 and 18 months, respectively, after the start of the discontinuation trial. All five assessments consisted of 
structured interviews carried out at the patients’ homes by trained interviewers, during which patients filled in 
various questionnaires, including the BCQ. For a more elaborate outline of the Benzoredux project and its study 
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ABSTRACT
Aim – To assess the scalability, reliability and validity of a newly constructed self-report 
questionnaire on craving for benzodiazepines (BZs), the Benzodiazepine Craving 
Questionnaire (BCQ).
Setting and participants – The BCQ was administered once to a sample of  long-term 
and 80 former long-term general practice BZ users participating in a large BZ reduction 
trial in general practice.
Measurements – () Unidimensionality of the BCQ was tested by means of the Rasch model. 
() The Rasch-homogeneous BCQ items were assessed for subject and item discriminability. 
() Discriminative and construct validity were assessed.
Findings – The BCQ met the requirements for Rasch homogeneity, i.e. BZ craving as assessed 
by the scale can be regarded as a unidimensional construct. Subject and item discriminability 
were good. Construct validity was modest. Highest significant associations were found with 
POMS depression (Kendall’s tau-c = 0.5) and Dutch Shortened MMPI negativism (Kendall’s 
tau-c = 0.4). Discriminative validity was satisfactory. Highest discriminative power was 
found for a subset of eight items (Mann–Whitney U z = -., p = 0.000). The first signs of 
craving are represented by the acknowledgement of expectations of positive outcome, 
whereas high craving is characterized by direct intention to use.
Conclusions – The BCQ proved to be a reliable and psychometrically sound self-report 
instrument to assess BZ craving in a general practice sample of long-term BZ users.
0
INTRODUCTION
Benzodiazepines (BZs) are among the most widely prescribed drugs in the western world 
and there have been many reports on their liability to cause dependence (e.g. among Dutch 
general practitioner (GP) patients,). Craving is regarded as an important aspect of 
dependence. It is posited frequently as having an influence on relapse and ongoing 
substance abuse.4,5 Although it is still an ill-defined concept with little consensus about its 
definition and theory, its causes and consequences and its measurement,-8 craving is likely 
to be experienced by most (if not all) individuals with substance dependence.9 Nevertheless, 
BZ craving research is scarce.
In a study by Lucki, Volpicelli & Schweizer patients who had discontinued their BZ use, 
including the long-term users, expressed little or no craving for the drug.0 Contrasting 
findings were reported by Linden, Bar & Geiselmann who argued that the refusal of about 
two-thirds of their general practice patients with long-term low-dose BZ dependence to 
accept a short drug-free intermission, provided evidence for drug seeking or craving 
behaviour. Apparently, these authors regarded craving to be the equivalent of drug 
insistence. Kan et al. suggested that about 84% of their general practice patients using BZs 
experienced craving, as operationalised by four items of the SCAN (Schedules for Clinical 
Assessment in Neuropsychiatry). Although the SCAN items were adapted for BZs, the 
validity of this approach has never been tested. 
As craving is generally regarded as a subjective phenomenon, its assessment in other 
substances of abuse is mainly based on self-reports. Most instruments to assess self-
reported craving are limited to questionnaires of unknown validity and reliability. Some 
use only one or two items to evaluate craving and approach craving as a unidimensional 
construct. Tiffany & Drobes took a different approach when they developed the 
Questionnaire on Smoking Urges (QSU). This is a self-report instrument directed at four 
different conceptual areas relevant to (cigarette) craving, in order to cover current craving 
theories as widely as possible: desire to use, anticipation of positive outcome, relief of 
withdrawal or (withdrawal-associated) negative affect and intention to use. The data 
obtained with the QSU showed multi-dimensional features of craving among smokers. A 
two-factor solution apparently best described the item structure. However, the two factor 
scales were fairly highly correlated, with high reliability coefficients for both factors.,4 
Studies illustrate that craving above all is a socially defined construct. In the absence 
of a unique objective referent for craving in the real world, the development of craving 
instruments should in our opinion focus on its usefulness as the second best option. Until 
now BZ withdrawal studies have not shown any consistent predictors for achieving and 
maintaining complete abstinence.5, As the role of craving in BZ withdrawal has never 
been evaluated, a reliable and valid instrument to measure BZ craving is needed to gain 
more insight into its role. It is not clear whether a multi-dimensional measure will have 
better predictive validity than a unidimensional scale. Nor is it clear which measure would 
be able to differentiate better between patients in terms of tailoring of treatment.
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The present study describes the development of the multi-item Benzodiazepine Craving 
Questionnaire (BCQ) to assess the extent of BZ craving, based on assumptions pertaining 
to the QSU developed by Tiffany & Drobes, including multi-dimensionality. The research 
questions of this study were: () can BZ craving be usefully construed as a multi-
dimensional concept? () Is the BCQ a reliable and psychometrically sound instrument to 
assess craving for BZs? Furthermore, initial indications of validity were explored.
METHODS
Setting
Patients from a large study on the efficacy of a two-part treatment intervention that aimed 
to reduce long-term BZ use in general practice in the Netherlands received a number of 
questionnaires, including the BCQ.7 The study started in 998. Patients’ responses to the 
BCQ formed the basis of present study.
Subjects and procedure
We identified long-term BZ users by means of a computerised search for BZ prescriptions 
at 0 general practices with 55 GPs. Long-term users were selected on the basis of the 
following two criteria: () having received BZ prescriptions for at least  months, and 
() having received prescriptions in an amount sufficient for at least 0 days in the 
 months prior to this study.
Exclusion criteria were: current psychiatric treatment, current treatment for drug or 
alcohol dependence, psychosis in medical history, epilepsy, insufficient mastery of the 
Dutch language, or suffering from a terminal illness. Patients could also be excluded 
specifically on the GP’s request because of severe comorbidity or for psychosocial 
reasons. 
When patients met the definition of long-term use, their GP sent them a letter with the 
advice to quit their BZ use gradually.7,8 Three months later they were invited to consult 
their GP to evaluate their current use status and the preceding period. The GP asked 
respondents to participate in the study. After full explanation of the study procedures, 
written informed consent was obtained from all participants. 
A total of 7 patients enrolled in the study, of whom 8 dropped-out before the first 
assessment. The remaining 89 patients participated in the baseline interview; about 4% 
had quit their use since receiving the letter from their GP. Due to a delay in the development 
of the questionnaire, not all the patients could be given the BCQ at baseline. However, 
analysis showed that there were no significant differences between the patients who received 
the BCQ at baseline (BCQ group, n = 9) and the patients who had not received the BCQ at 
baseline (n = 8), or had received the BCQ, but had missing BCQ values (n = 4).




During the baseline interview data were gathered on BZ use and socio-demographic 
characteristics. In addition to the BCQ, the following questionnaires were administered: an 
8-item self-report questionnaire to measure the extent of problem drinking (alcohol users 
only);9 the Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ), a 0-item self-
report questionnaire to assess BZ withdrawal symptoms during discontinuation;0, the 
Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ), a 0-item self-
report questionnaire, consisting of four Rasch homogeneous scales, to measure the severity 
of BZ dependence; the Dutch Shortened MMPI (NVM) to assess personality traits; the 
Profile of Mood States Dutch shortened version (POMS), a -item self-report questionnaire 
to measure five short-term changeable mood states;4 and the General Health Questionnaire 
-item version (GHQ-) to assess psychological well-being (sum score according to 
Goldberg).5 All questionnaires show good reliability and validity. The BCQ was developed 




Items for the BCQ were generated to represent four distinct conceptualizations of drug 
urges, in line with Tiffany & Drobes: () desire to use; () anticipation of positive outcome 
from BZ use; () anticipation of relief from withdrawal or withdrawal-associated negative 
affect; and (4) intention to use. A fifth category, ‘lack of control over use’, was derived 
from the Cocaine Craving Questionnaire (CCQ). The QSU and CCQ are assumed to have 
satisfactory psychometric properties.
The 50 items ( from the QSU and 8 from the CCQ) were translated into Dutch and 
back into English to ensure correct translation. To obtain a good face validity, the items 
were judged by eight experts in the field of BZ research. Some adaptations were made to 
achieve clearer comprehension in Dutch and better application to BZ use. In the next 
phase, eight BZ users were asked to fill in the resulting questionnaire and comment on 
comprehensibility, ambiguity and recognition. Some items were altered subsequently or 
removed. The remaining 48 items constituted the initial BCQ. The order of statements in 
the BCQ was determined at random.
Format
At the top of the BCQ the interviewer noted the current date, current time and time and 
date of the patient’s last BZ consumption. In the second section, patients completed the 
BCQ according to their current feeling, by indicating the extent to which they agreed or 
disagreed with each item on a seven-point Likert-type scale. The end points of the scale 
were labelled ‘strongly disagree’ () and ‘strongly agree’ (7).
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Data analyses
All data analyses were conducted using SPSS 0.0.5 with the exception of the Rasch 
analyses, which were conducted using the Rasch Scaling Program (RSP).7 Initial factor 
analyses were used to explore dimensionality. These were followed by Rasch analyses to 
test more strict assumptions.
Factor analysis
We performed exploratory factor analysis on our data using principle axis extraction for 
factor determination with the promax rotation method (power = ), in line with Tiffany & 
Drobes. To test the goodness-of-fit of the factor structure, we also performed a maximum 
likelihood factor analysis. We did not expect the five conceptualizations of craving to 
emerge as distinct factors in the factor analysis, because they have not done so in previous 
research.,,8,9
Rasch analysis
One important reason for using the Rasch model is that it is the only one in which a 
subject’s sum score is a ‘sufficient statistic’ for the underlying unidimensional latent trait,0 
i.e. the sum score reflects all information that is contained in the item scores. Although in 
factor analysis sum scores are also used, different information is contained in the item 
scores, thereby obscuring the associations under investigation (e.g. population characteristics 
are well-known confounders of factor structures). 
Furthermore, in questionnaire research continuous single peaked item characteristic 
curves (ICCs) may occur occasionally, which do not justify the use of sum scores. Rasch 
homogeneity requires continuous strictly monotone increasing ICCs, a requirement which 
is accounted for in Rasch analysis. 
A third assumption tested in Rasch analysis is local stochastic independence. The two 
questions ‘Do you crave?’ and ‘Does it feel bad?’, for example, are not local stochastic-
independent, the latter depending on the former. In Rasch analysis, people who admit to 
an item indicating serious craving problems will also admit to the preceding ‘less serious’ 
items, so subjects can be ranked according to craving severity. This is another advantage 
over factor analysis. 
Glas developed two statistical tests for the dichotomous Rasch model, known as R and 
R. The statistics R and R are especially sensitive to the property of equi-discriminability 
(R) and to uni-dimensionality and local stochastic independence (R). If R is not 
significant (p > 0.0), the null hypothesis that all the items have equal discriminative power 
cannot be rejected and equi-discriminability can be assumed. The same applies to R. 
Rasch homogeneity is accepted if both R and R hold true. The respective values of R and 
R are dependent on the method that is used to estimate the subject and item parameters. 
In this paper the method of Conditional Maximum Likelihood (CML) was used.




In order to estimate the reliability of the BCQ, subject discriminability and item 
discriminability were assessed. To test subject discriminability (internal consistency) the 
Kuder–Richardson-0 coefficient (KR-0) was computed. The KR-0 is the equivalent of 
Cronbach’s alpha for dichotomous items. The size of the KR-0 reflects the reliability of 
the scale. 
Item discriminability was tested by Cochran’s Q-test. The item discriminability 
coefficient (IDC, described first by Kan et al.) was computed to show the extent to which 
the differences between items are systematic.
Validity
In order to determine the validity of the BCQ, construct and discriminative validity were 
assessed. To establish construct validity sum scores of the BCQ were associated with 
BWSQ, Dutch Shortened MMPI, Bendep-SRQ, GHQ-, POMS and nicotine, alcohol and 
coffee consumption. 
The discriminative validity was investigated by assessing associations of the BCQ with 
current use of or abstinence from BZs.
RESULTS
Socio-demographic features and pattern of BZ use
Table  shows the socio-demographic characteristics and mean values for BZ dose and 
duration of use in the total BCQ sample. 
The majority of patients were elderly, female, married, had a secondary education level 
and were living on a pension. Compared to the men in our population, the women were 
significantly more often (χ, p < 0.05) divorced or widowed, living alone, living on their 
partner’s income or on a pension and more often had a primary education level. Men used 
alcohol more often (χ, p = 0.0), on average consumed more units per day (Mann–Whitney 
U, p = 0.00) and were more often classified as problem drinkers (χ, p = 0.004).
On average, BZ dosage did not exceed the therapeutic dosage recommended by the 
World Health Organization (WHO). Patients had been using BZs from a duration of 4 
months up to a maximum of  years and 99.5% of the patients for a duration of  months 
or longer. Concerning BZ dependence, based on the Bendep-SRQ subscale scores, the 
average severity of BZ dependence in our population was low. At the time of the interview, 
4.5% of the total BCQ group (n = 80) had quit their use in the  months after receiving the 
letter from their GP.
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Table 1 Subject characteristics of the BCQ sample
Total BCQ sample  (n = 193) 
 n/mean %/SD
Background characteristics
Age, mean (SD) years 62.9 12.0
Female 131 67.9%
Marital status
 No relationship 13 6.7%
 Steady relationship (incl. married) 127 65.8%
 Divorced 10 5.2%
 Widowed 43 22.3%
Living alone 61 31.6%
Highest level of education
 Primary level 61 31.6%
 Secondary level 123 63.7%
 Advanced 9 4.7%
Financial income
 Income by profession 27 14.0%
 Unemployment benefit 9 4.7%
 Disability benefit 27 14.0%
 Pension 90 46.6%
 Partner’s income 26 13.5%
 Otherwise 14 7.3%
Smoking
 Smoking (cigarettes/cigars/pipe) 80 41.5%
 Mean (SD) cigarettes/day among cigarette smokers (n = 79) 16.5 10.9
Alcohol use
 Drinking alcohol 98 50.8%
 Mean (SD) units/week among drinkers 9.6 8.4
 Problem drinkers among drinkersa 16 16.3%
Coffee use
 Coffee users 130 67.4%
 Mean (SD) units/day among coffee users 4.4 2.8
Benzodiazepine use
Quit after letter with advice to quit BZ use 80 41.5%
Daily dosage, mean (SD) in mg diazepam equivalents 6.9 8.1
 Quartiles 2.9 - 5.0 - 7.8
Duration of use, mean (SD) in monthsb 129.9 108.2
 Quartiles 48.0 - 96.0 – 186.0
Benzodiazepine dependencec, mean (SD) total score
 Problematic use (n = 191) 1.2 1.2
 Preoccupation (n = 192) 1.4 1.6
 Compliance (n = 192) 0.3 0.7
 Withdrawal (n = 178) 1.1 1.6
a Score ≥ 3 on Cornel Questionnaire19
b Based on patients who quit and did not quit in the previous three months.
c Based on the Bendep-SRQ33




Visual inspection of the data and feedback from the interviewers indicated that many 
patients misinterpreted the reverse-keyed items as the opposite of their intended meaning, 
or simply did not understand these items. These items were left out of the analyses; 
 items remained.
Factor analysis
Principal axis factor analysis with the promax rotation method as conducted by Tiffany & 
Drobes on the QSU data revealed six factors with eigen values greater than . The first 
factor accounted for 47.8% of the item variance and the remainder for a total of 9.%, 
which suggested one main factor in our data. Kaiser–Meyer–Olkin measure of sampling 
adequacy was high (0.9), which indicated that our data were suitable for factor analysis. 
However, when we tried to confirm these one and six factor solutions with the aid of the 
maximum likelihood factor analysis, no factor solution with a non-significant goodness-
of-fit test was found: all χ df ratios were greater than . Goodness-of-fit was also significant 
for maximum likelihood factor analysis with eigen values greater than . These findings 
appeared to be caused by skewed data. Consequently, further interpretation of factor 
analysis data was not considered appropriate.
Rasch analysis
Data inspection showed that six patients had given mainly the same answer to all the 
items. They were omitted from the analyses, which left 87 patients. All items of the BCQ 
were dichotomized between option four and option five of the seven-point Likert scale. 
This procedure resulted in 59 subjects for Rasch analysis with non-zero variance. 
Investigating the dimensionality, initial analyses showed that several items made large 
contributions to R or R, which disrupted the unidimensionality and local stochastic 
independence. These items were excluded from further Rasch analyses; final outcomes are 
shown in Table  for 0 items. The R and Q statistics were non-significant for all 
0 items. (The Q statistic was used as an estimation of R due to the large number of 
items.) The results demonstrated that this 0-item BCQ meets the requirements for the 
Rasch model and can thus be considered a Rasch homogeneous scale. The English 
translation of the complete 0-item version of the BCQ, including the scale values for each 
item, is presented in the Appendix.
Reliability
Subject discriminability (internal consistency)
The KR-0 value was very high (0.94), which indicated that the BCQ has substantial 
differentiating power between patients.
Item discriminability
The high IDC value (0.8) and statistically significant results of Cochran’s Q-test (Q = 7.5, 
p < 0.00) indicated good item discriminability.
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Table 2 Test results of CML Rasch analysis on BCQ items by means of Rasch Scaling Program (RSP)a
Parameter Value
No. of items in the scale 20
R1 (test statistic for equi-discriminability) 12.08
Degrees of freedom for R1 19
p-value R1 .8820
No. of subgroups formed by Rasch analysis 2
Q2 (test statistic for unidimensionality and local stochastic independence) 132.03
Degrees of freedom for Q2 approx. 170
p-value Q2 .9861
No. of patients remaining in the analysis 59
a Due to rounding-off error in the computational procedure of R2 using the original Rasch scores, the fit of the Rasch model 
is reported based on inverted Rasch scores (0 = 1 and 1 = 0). This inversion has no effect on the outcomes. The Q2 statistic 
was used as an estimation of R2 due to the large number of items.
Validity
Discriminative validity
The mean scores on the BCQ for the total population were low (mean = ., SD = ., 
median = 0.0). As reflected in Fig. a,b, patients who did not quit their BZ use after the 
letter from their GP (n = ) scored significantly higher on the BCQ, i.e. experienced more 
severe craving, than patients who had quit (n = 80) (Mann–Whitney U = 44.0, z = - .7, 
p = 0.00). Of the former group 40.7% (n = 4) reported craving to some extent, in contrast 
to .5% (n = 8) of the latter group. Patients still using BZ who experienced craving 
reported using significantly higher daily BZ dosages than patients who did not experience 
craving (9. mg (SD = .) versus 5. mg (SD = 4.) diazepam equivalents, p = 0.08).
With regard to the utility of the questionnaire we found eight items that distinguished 
bivariately current BZ users from patients who had recently quit their use with p < 0.05 (see 
Appendix items printed in bold). These items formed a reliable scale (KR-0 = 0.87) and yet 
covaried considerably with the non-discriminating items (r = 0.89). Not surprisingly, 
discriminative power was higher for these eight items (Mann–Whitney U = 557.0, z = -., 
p = 0.000). Apart from this, several individual items from the original 48-item version of the 
BCQ distinguished current BZ users from patients who had recently quit their use. These 
items did not constitute a scale; reliability was 0.58. Setting alpha to 0.00, three items 
remained: ‘I could hardly feel better physically if I had taken a BZ’ (χ = 5.5, df = ), 
‘Starting now, I could go without a BZ for a long time’ (χ = 4., df = ), and ‘If I took a BZ 
right now, I would hardly sleep better’ (χ = 8., df = ). Patients who had recently quit 
their use scored higher on the single items than patients still using BZs, reflecting a higher 
perceived control to do without BZs. Only ‘Starting now, I could go without a BZ for a long 
time’ correlated significantly with the eight-item subscale (r = 0., p < 0.0).





Figure 1 (a) Histogram of BCQ total scores for patients who had not quit their BZ use
(n = 113; mean = 1.7; SD = 4.1; median = 0.0); (b) Histogram of BCQ total scores for
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Construct validity
In general the associations of the BCQ-scores with measures of related constructs were low 
(see Table ). Highest significant associations were found with depression, negativism, 
GHQ- sum score, somatisation, preoccupation and withdrawal symptoms. The subset of 
eight items discriminating between BZ users and patients who had recently quit their use 
showed a significant association with anger, an increased association with preoccupation 
and withdrawal symptoms, and decreased associations with GHQ- sum score, negativism 
and depression. The two single items ‘Starting now, I could go without a BZ for a long time’ 
and ‘If I took a BZ right now, I would hardly sleep better’ were negatively associated with 
dependence measures (both items) and psychopathology (‘…, I could go without a BZ for a 
long time’ only).
Table 3 Associations between BZ craving and related constructs (Kendall’s Tau-c)
Scale A B C D E
BWSQ2 sum score .11 .12 .02 -.20 .09
Bendep-SRQ
 Problematic use .08 .10 -.11 -.24 -.22
 Preoccupation .13 .18 -.11 -.36 -.23
 Lack of Compliance .04 .05 .00 -.10 -.04
Dutch Shortened MMPI
 Negativism .14 .11 .04 -.14 .01
 Somatisation .13 .13 -.09 -.17 -.03
 Shyness .07 .05 .04 -.13 .04
 Psychopathology .09 .08 .01 -.21 .08
 Extraversion .06 .03 .04 .10 .04
GHQ-12 sum score (Goldberg) .13 .12 -.05 -.19 -.09
POMS
 Depression .15 .12 -.07 -.19 .10
 Anger .10 .11 .03 -.15 .08
 Fatigue .11 .08 .03 .00 .15
 Vigour -.05 .00 .14 .06 -.05
 Tension .11 .11 -.05 -.17 .08
Coffee use -.08 -.08 .00 -.00 -.14
Nicotine use .01 .05 -.09 -.00 .02
Alcohol use -.09 -.06 -.07 -.00 .04
Digits in bold represent p < 0.01
A = 20-item BCQ Rasch homogeneous scale. B = 8-item Rasch homogeneous subscale, distinguishing current BZ users 
from patients who had recently quit their use. C-E = single non-Rasch homogeneous items, distinguishing current BZ users 
and patients who had recently quit their use. C: ‘I could hardly feel better physically if I had taken a BZ’; D: ‘Starting now, I 
could go without a BZ for a long time’; E: ‘If I took a BZ right now, I would hardly sleep better’.
DISCUSSION
To our knowledge, the BCQ is the first multi-item instrument that has been developed to 
assess BZ craving. In contrast with most existing craving measures for other substances, 
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the psychometric properties of the BCQ have been assessed in detail. The main findings of 
our study were:
1 The 0-item BCQ met the criteria for Rasch homogeneity and thus the items could be 
ranked according to ‘craving intensity’ on a unidimensional scale. This means that 
people who admit to an item indicating serious craving problems will also admit to the 
preceding ‘less serious’ items, i.e. the BCQ measures the extent to which people crave 
BZs. The sum score of the BCQ was a sufficient statistic of the underlying dimension, 
i.e. craving.
2 The BCQ proved to have good reliability. Construct validity, however, did not turn out 
as we had expected. Given the unidimensionality of the BCQ, it is possible that 
obsession with respect to the availability of BZs constitutes only a minor part of the 
craving dimension. Using a subset of items could increase the discriminative validity, 
maintaining sufficient reliability and validity.
Our finding that craving is a unidimensional construct indicates that craving can be 
defined as a continuum from (almost) none to very high. Although the 0-item BCQ 
appeared to be unidimensional, it contains items from the five conceptual craving 
categories: desire to use, anticipation of positive outcome, relief of withdrawal or 
(withdrawal-associated) negative affect, intention to use and lack of control. Roughly 
speaking, the items most commonly admitted to by the respondents were from the 
categories anticipation of positive outcome and anticipation of relief from withdrawal or 
negative affect. These items are located at the lower end of the Rasch rank order and 
reflect a moderate extent of BZ craving. This suggests that all subjects who experience 
craving expect BZs to modulate their emotions, suggesting cognitive reflection upon its 
effects. The items admitted to by the patients only with the most severe craving were from 
the categories intention to use, desire to use and lack of control. This suggests that in 
addition to the cognitive character high craving is explicitly goal-orientated.
Our study had several limitations. Differences in patients, item sets, language and 
substance may have contributed to the disparity between the results of the three studies 
(CCQ, QSU and BCQ). The BCQ sample consisted of long-term BZ users who had either quit 
their use recently or had failed to do so, but still appeared motivated to quit, as concluded 
from their willingness to visit their GP. The smokers and cocaine users studied by Tiffany 
& Drobes and Tiffany et al. were not selected on the intention to quit. 
Although the items in the BCQ were similar to those in the QSU and CCQ, translation 
and modification of the items from the latter questionnaires resulted in a somewhat 
different item pool. Concerning the item formulation, we do not have an explanation for 
the misinterpretation of the reverse-keyed items. Sweeney, Pillitteri & Kozlowski explored 
the effect of item wording on responses to the QSU by Tiffany and colleagues.4 Some 
negatively worded statements proved to be especially troublesome for their respondents. 
However, they could not detect any consistent patterns in their results that would provide 
an explanation either. Therefore, although the initial purpose of reverse-keyed items was 
to prevent response tendencies, we suggest for future research to avoid this methodology.
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The fact that Tiffany & Drobes, Tiffany et al. and Love et al. did not use confirmatory 
factor analyses to test their factor models means that a unidimensional description of 
craving may also apply to other substances. They did find, however, that first-order 
nicotine, cocaine and alcohol craving factors all loaded strongly on single, second-order 
factors. Further evidence to suggest that craving (its structure) is roughly the same for all 
substances was reported by Bohn et al.8 They developed the 49-item Questionnaire of 
Alcohol Urges (QAU), which was a preliminary version of the eight-item Alcohol Urge 
Questionnaire (AUQ) and based partly on the CCQ and QSU of Tiffany and colleagues. They 
found a reasonably good fit with a single-factor structure. The highest loading items of the 
QAU came from the categories that reflected high craving as measured by the BCQ (desire, 
lack of control), although used methods are incomparable.
Clearly, good psychometric characteristics may be considered only a basic requirement 
for usefulness of an instrument. Conclusions with respect to the predictive validity of the 
BCQ and its use in clinical practice (e.g. the ability to measure changes in craving) and 
scientific research cannot be made on the basis of the present cross-sectional data. Further 
research is needed to reveal the utility of the BCQ in terms of its contribution to the under-
standing of BZ dependence and the effectiveness of interventions. Follow-up data gathered 
at different stages of BZ reduction in our study may provide more insight in these matters.
As for clinical interpretation of the BCQ scores, the majority of patients hardly 
experience any craving at all, either while still using or after having quit. A tentative 
explanation for this low prevalence of craving may be that most BZs act slowly and have 
long half-lives. Upon cessation of quick- and short-acting stimulants, such as cocaine or 
nicotine, craving is reported to a much higher extent (e.g. 5-7). Notwithstanding the above, 
the most reported (low) craving for BZs does seem to be dominated by outcome expectancies 
(anticipation of positive outcome and anticipation of relief from withdrawal or negative 
affect), whereas in a minority of patients who experience high craving it is characterized 
by lack of control, and intention and desire to use. Possibly, there is a subgroup of BZ users 
that is more sensitive to the craving inducing effects of BZs than others.
Concerning the discriminative power of the subset of eight items, which stem from the 
lower and middle regions of craving severity, the power of this study is too low for the 
high craving items to discriminate between BZ users and patients who had recently quit 
their use, given the low percentages of affirmative answers. From the construct validity 
analysis it appears that the subset of eight items refers more to preoccupation and less to 
negativism and depression. However, this conclusion may be premature with the differences 
being so small. Although the three single discriminating items do not constitute a scale, 
they seem to refer to a construct opposite to craving, comparable to behavioural control 
(e.g. 8). This is reflected by negative associations with dependence and psychopathology. 
However, we should keep in mind the remarks by Sweeney et al. about possible 
misinterpretation of negatively worded statements.4
Cross-validation data may reveal these and other differences in experienced craving 
severity between general practice BZ users and BZ users from other settings.
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APPENDIX
Rasch-homogeneous BCQ itemsc with Rasch scale value estimates, standard errors, questionnaire of origin (QSU or
CCQ) and item category of origin, and item number, placed in order of level of craving (high to low)
Item B SE(B) Q/C, Cat Item no.
I would hardly be able to stop myself from taking a BZ if I had some here now -1.391 .690 C,5a 7
I crave a BZ right now -.969 .617 Q,1 5
I must take a BZ now -.969 .617 Q,1a 6
If I were offered a BZ, I would take it immediately -.969 .617 Q,4 12
All I want right now is a BZ -.969 .617 Q,1 17
I am going to take a BZ as soon as possible -.969 .617 Q,4 18
I will take a BZ as soon as I get the chance -.969 .617 Q,4 20
I would do almost anything for a BZ now -.617 .559 Q,4 3
Nothing would be better than taking a BZ right now -.617 .559 Q,2 9
I want to take a BZ now -.318 .514 Q,1a 13
Right now I have an urgent need to take a BZ -.062 .478 Q,1a 11
I would enjoy a BZ right now -.062 .478 Q,2a 15
I would hardly be able to control how many BZ I took if I had some here .357 .425 C,5a 4
If I took a BZ right now I would feel less inhibited .691 .389 2b 16
I could control things better right now if I could take a BZ .835 .375 Q,3 14
I would feel energetic if I took a BZ .835 .375 C,2 19
I am missing my BZs right now 1.093 .353 Q,1a 2
Taking BZ right now would make me feel less tired 1.093 .353 Q,3 8
Taking a BZ would make me feel very good right now 1.950 .301 Q,2 1
Taking a BZ would make me feel less depressed 2.027 .297 Q,3 10
a Items 2, 13 and 15 were originally reverse-keyed items; items 4 and 7 were originally negatively worded items; items 6 
and 11 were rephrased for clearer comprehension in Dutch.
b Item 16 was completely adapted for BZs, not present in QSU nor in CCQ.
c Respondents were instructed to substitute their specific benzodiazepine(s) for ‘BZ’.
B: Rasch scale value estimate. Note that for purposes of analyses high values indicate low craving.
SE: standard error of the Rasch scale value estimate B.
Q/C: Q = item originated from Questionnaire on Smoking Urges; C = item originated from Cocaine Craving Questionnaire. 
Cat: 1 = desire to use; 2 = anticipation of positive outcome; 3 = relief of withdrawal or negative affect; 4 = intention to 
use; 5 = lack of control.
Items printed in bold were univariately associated with abstinence/current use.
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ABSTRACT
Background – The aim of this study was to () describe the characteristics of patients 
reporting craving for benzodiazepines (BZs) and () to search for associations between BZ 
craving and other clinical variables in a population of general practice (GP) patients who 
have made an attempt to discontinue their long-term BZ use.
Methods – The Benzodiazepine Craving Questionnaire (BCQ) and other self-report 
questionnaires were administered once to a population of  long-term and 80 former 
long-term GP BZ users participating in a large BZ reduction trial in GP. Cross-sectional 
data were gathered on self-reported BZ craving (BCQ), self-reported BZ dependence 
severity (Bendep-SRQ), psychopathology (General Health Questionnaire -item version; 
Medical Outcome Study Short-Form -item version), mood state (Profile of Mood States), 
personality (Dutch shortened MMPI), and lifestyle characteristics. Differences between 
patients who reported craving and patients who did not were analyzed univariately. 
Multivariate analyses were performed on variables significantly associated with craving, 
controlling for current use status.
Results – () Patients reporting craving differed significantly from patients not reporting 
craving on aspects of BZ dependence severity, psychopathology, negative mood state, and 
personality. () Negative mood and somatization were positively associated with BZ craving, 
although only the contribution of negative mood to craving was statistically significant for 
the total group of (former) BZ users (p = .00).
Conclusions – Self-reported negative mood and somatization are positively associated with 




Craving is a psychobiological phenomenon that is regarded as an important aspect of 
dependence. In International Statistical Classification of Diseases, 0th Revision, but not in 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, a ‘strong desire or 
compulsion’ to use a drug is one of the diagnostic criteria for dependence., 
Empirical research and psychological theories and models on craving tend to focus on 
craving for alcohol, nicotine, cocaine, and opiates. From a theoretical perspective, the 
occurrence of craving has been associated grossly with (a) dependence and drug-use 
aspects (i.e., aversive aspects of the drug-withdrawal syndrome and positive reinforcing 
drug effects), (b) mood states, and (c) cognitive labeling (i.e., craving representing the 
cognitive labeling of physiological processes) (e.g. Refs -). Each theoretical model provides 
a different conceptualization of craving, but none of these models provide a full explanation 
of the craving phenomenon, suggesting that multiple mechanisms may be involved.4,7 
Experiments to compare theories with one another have not been conducted yet.
From an empirical perspective, there is evidence, although sometimes inconsistent, 
that craving is associated with (a) personality factors, such as sensation seeking, 
impulsiveness, neuroticism, extraversion; (b) (situation specific) mood states;8,0 
(c) dependence;9,0 (d) psychopathology (such as a general negative affective state, i.e. 
depressive symptomatology).
Despite the accumulating evidence for benzodiazepines (BZs) to cause dependence 
e.g.,4), and the fact that they are widely prescribed in the Western world,5 craving 
research on BZs has hardly been done (for a discussion, see Ref ). In an attempt to fill this 
gap, the -item Benzodiazepine Craving Questionnaire (BCQ), the first multi-item 
instrument to assess BZ craving, was developed recently. The BCQ was based on the 
Questionnaire on Smoking Urges and the Cocaine Craving Questionnaire.7,8 It proved to 
be a reliable and valid Rasch homogeneous self-report craving measure in a general 
practice (GP) population of long-term BZ users.
The goal of the present study is () to expand our knowledge on BZ craving, that is, to 
describe the characteristics of patients experiencing BZ craving and to describe which 
subject-related variables were associated with BZ craving in a population of GP patients 
who recently discontinued their long-term BZ use or failed to do so. () We seek to determine 
to what length our data would support existing craving theories and empirical findings on 
craving occurrence. We used the BCQ as the measure for BZ craving. Based on associations 
frequently found with craving in other substances, associations with variables from the 
following domains were investigated with both univariate and multivariate approaches: 
BZ dependence (severity), psychopathology, mood state, personality, and lifestyle.
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Patients from a large study on the efficacy of a -part treatment intervention that aimed to 
reduce long-term BZ use in GP in the Netherlands completed a number of questionnaires.9,0 
The study was carried out between August 998 and December 00. Patients’ responses to 
the BCQ at first assessment (baseline interview) formed the basis of the present study.
Subjects and procedure
We identified long-term BZ users (i.e., use for more than  months) by means of a 
computerized search for BZ prescriptions at 0 general practices with 55 GPs and a total of 
about 8000 patients. Exclusion criteria were current psychiatric treatment, current 
treatment for drug or alcohol dependence, medical history of psychosis, epilepsy, 
insufficient mastery of the Dutch language, or a terminal illness. Furthermore, patients 
could be excluded specifically on the GPs request, because of severe comorbidity or for 
psychosocial reasons. Patients who met the definition of long-term use (n = 004) were 
sent a letter by their GP with the advice to discontinue their BZ use gradually.9, Three 
months later, they were invited to consult their GP to evaluate their current BZ use status 
and the preceding period. At this consultation, the GP asked the respondents (n = ) to 
participate in the study. After full explanation of the study procedures, 7 patients 
provided written informed consent to participate in the study.
Sample size
Of the 7 patients who enrolled in the study, 8 patients dropped out before the first 
assessment. The remaining 89 patients participated in the baseline interview. Not all the 
patients could be given the BCQ at baseline, because of a delay in the development of the 
questionnaire. However, analysis showed that there were no significant differences between 
the patients who received the BCQ at baseline (n = 9) and the patients who had not 
received the BCQ (n = 8) or had received the BCQ but had missing BCQ values (n = 4). At 
the time of the interview, about 4% of the patients who received the BCQ at baseline had 
discontinued their use in the  months after receiving the letter from their GP (80/9).
Measures
During the baseline interview, the BCQ was administered. Information on lifestyle was 
obtained: sociodemographic characteristics, nicotine, alcohol and caffeine use, and data 
from a questionnaire measuring the extent of problem drinking (alcohol users only). 
Dependence characteristics were obtained assessing BZ use features, severity of BZ 
dependence (Bendep-SRQ),,4 and BZ withdrawal symptoms during discontinuation 
(BWSQ).5, We used the Dutch shortened MMPI (NVM) to assess personality traits: 
negativism, somatization, shyness, psychopathology, and extraversion,7 and the Profile of 
Mood States (POMS) Dutch shortened version, to measure 5 short-term changeable mood 
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states (depression, anger, fatigue, vigor, and tension).8 Presence and severity of 
psychopathology were assessed with the General Health Questionnaire -item version 
(GHQ-), a measure of psychological well-being,9 and the Medical Outcome Study Short-
Form -item version (MOS SF-), a measure of health-related quality of life on 8 different 
health domains (physical functioning, role functioning - physical problem, role functioning 
- emotional problem, vitality, mental health, social functioning, pain, and general health).0 
All questionnaires were multi-item, self-report scales with satisfactory reliability and 
validity. Specially trained interviewers interviewed the patients at their homes
Data analyses
All data analyses were done using SPSS 0.0.5 (SPSS Inc, Chicago, Ill). To analyze 
differences on independent variables between patients who reported craving and patients 
who did not, we used Pearson χ test and Mann-Whitney U test. After controlling for 
potential interaction effects of current use status via bivariate logistic regression analysis, 
variables still significantly associated with craving were entered into a multivariate logistic 
regression analysis using forward and backward elimination procedures, with craving yes/
no as the dependent variable. For explorative purposes, all p-values were initially set 
at .05. For the final multivariate tests, α was set to .00, correcting for multiple testing 
(Bonferroni correction).
RESULTS
Characteristics of the study participants
Table  shows the characteristics of the study participants who received the BCQ at 
baseline. The majority of patients were elderly, female, married, had a secondary-education 
level, and were living on a pension. About half of the patients used alcohol and/or nicotine, 
and the majority used caffeine. On average, BZ dosage did not exceed the therapeutic 
dosage recommended by the World Health Organization. Given the skewed distribution of 
the craving data, momentary craving for BZs was coded as a dichotomous variable: 0 if a 
patient reported no craving for BZs at all, and  if any craving for BZs was present. About 
% of the patients indicated experiencing craving to some extent.
However, the average BCQ score (i.e., the average craving severity) was low. Scores on 
the withdrawal symptoms questionnaire were lower than those found by Tyrer et al5 in a 
population of putative pharmacological dependent patients. The overall average severity 
of BZ dependence in our population was low. Based on the norm scores of the Dutch 
Shortened MMPI for the general Dutch population, our patients scored high on 
somatization, above average on shyness, and below average on extraversion. Patients 
rated their overall health-related well-being or functioning about 0 to 0 points lower 
than the averages of the Dutch population. Based on a cutoff rate of two third on the 
GHQ-, % of the patients could be classified as ‘psychiatric cases’. As for the POMS 
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subscales, the proportion of patients in the fifth quintile was 40% for depression, 5% for 
anger, % for fatigue, 8% for having no vigor, and 9% for tension, based on the sex-
adjusted norm scores for the Dutch population.8
Table 1 Subject characteristics of the BCQ population
Total group  (n = 193) 
 n/mean %/SD
Background and lifestyle characteristics
Female 131 67.9%
Age, mean (SD) in years 62.9 12.0
Marital status
 No relationship 13 6.7%
 Steady relationship (including married) 127 65.8%
 Divorced 10 5.2%
 Widowed 43 22.3%
Living alone 61 31.6%
Highest level of education
 Primary level 61 31.6%
 Secondary level 123 63.7%
 Advanced 9 4.7%
Financial income
 Income by profession 27 14.0%
 Benefit (unemployment or disability) 36 18.7%
 Pension 90 46.6%
 Partner’s income 26 13.5%
 Otherwise 14 7.3%
Nicotine use
 Nicotine users 80 41.5%
 Mean (SD) cigarettes per day among cigarette smokers (n = 79) 16.5 10.9
Alcohol use
 Drinking alcohol 98 50.8%
 Mean (SD) units per week among drinkers 9.6 8.4
 Problem drinkers among drinkersa 16 16.3%
 Cornel score (n = 98), mean (SD) total score 1.0 1.7
Caffeine use
 Caffeine users 130 67.4%
 Mean (SD) units per day among caffeine users 4.4 2.8
Benzodiazepine use 
Duration, mean (SD) in monthsb 129.9 108.2
Daily dosage at assessment, mean (SD) in mg diazepam equivalentsc 6.9 8.1
Daily dosage previous 3 months, mean (SD) mg diazepam equivalentsd 6.7 6.9
Discontinued after letter from GP with advice to discontinue BZ use 80 41.5%
Craving
Craving severity (BCQ), mean (SD) total score 1.2 3.2
 No craving (total score = 0) 129 66.8%
 Craving (total score > 0) 64 33.2%
Dependence characteristics
Withdrawal symptoms (BWSQ2) (n = 191), mean (SD) total score 6.1 6.7
BZ dependence severity (Bendep-SRQ), mean (SD) total score
 Problematic use (n = 191) 1.2 1.2
 Preoccupation (n = 192) 1.4 1.6
 Lack of compliance (n = 192) 0.3 0.7
 Withdrawal (n = 178) 1.1 1.6
Table continues on the next page
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 Table 1 continued n/mean %/SD
Personality characteristics
Dutch Shortened MMPI (NVM), mean (SD) total score
 Negativism 12.2 7.5
 Somatization 14.0 7.8
 Shyness 10.5 7.1
 Psychopathology 2.9 3.1
 Extraversion 13.2 5.6
Psychopathology
Psychological wellbeing (GHQ-12, Goldberg), mean (SD) total score (n = 192) 2.0 3.1
Health related quality of life (MOS SF-36), mean (SD) (range 0 - 100)
 Physical functioning 68 26
 Role functioning – physical problem (n = 192) 60 41
 Pain 64 25
 General health perception 58 22
 Vitality 58 23
 Social functioning 66 21
 Role functioning - emotional problem 69 40
 Mental health 68 19
Mood state
Short-term changeable mood states (POMS), mean (SD) total score
 Depression 12.8 6.2
 Anger 11.0 5.1
 Fatigue 12.2 5.9
 Vigour 15.0 4.7
 Tension 11.8 5.5
a Score ≥ 3 on Cornel Questionnaire.22
b Based on patients who discontinued and did not discontinue their BZ use in the previous 3 months.
c Current BZ users only.
d Based on recorded consumption extracted from the GP’s clinical database.
Associations with BZ craving
The Bendep-SRQ subscale withdrawal was left out of the analyses because patients only 
filled in the withdrawal section of the Bendep-SRQ if they had ever discontinued or 
attempted to discontinue their BZ use in the past. 
As many as  variables were found to be significantly correlated with craving in 
univariate analyses at p < .05. In the group that reported craving for BZs (n = 4), 
significantly fewer patients had discontinued their BZ use in the  months after receiving 
the letter from their GP than in the group that did not report craving (n = 9). Craving was 
reported by .5% (8/80) of the patients who had discontinued their use vs 40.7% (4/) 
of those who had not. Of all patients who experienced craving, 7.8% (4/4) were still 
using BZs compared with 5.9% (7/9) of all patients who did not experience craving 
(see Table A). With respect to the subgroup that failed to discontinue its use (n = ), 
patients reporting craving used BZs in significantly higher daily dosages than patients not 
reporting craving (see Table B). 
Patients reporting craving scored significantly higher on the withdrawal symptoms 
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questionnaire and were significantly more often preoccupied with the availability of BZs. 
They also scored significantly higher on Dutch Shortened MMPI subscales negativism 
(respectively average vs below average as compared with the general Dutch population), 
somatization (very high vs high), and psychopathology (high vs average) than did patients 
who did not report craving. Patients reporting craving rated their health-related quality of 
life significantly lower on 4 of 8 subscales and about 5 to 0 points lower than the 
averages of the Dutch population. Thirty-nine percent of the patients reporting craving 
could be classified as ‘psychiatric cases’ vs 0% in the nonreporting group. Patients 
reporting craving scored significantly higher on POMS subscales depression, anger, fatigue, 
and tension. The proportions of patients in the fifth quintile were respectively 48% vs % 
for depression, % vs % for anger, 45% vs % for fatigue, and 9% vs % for tension 
(see Table B).
As about 4% of the population had discontinued their BZ use, which led to missing data 
on BZ dosage for these patients, mean daily BZ dosage was left out of further analyses. 
Patients who had discontinued BZ use and patients who were still using BZs differed 
significantly on BCQ sum scores. Therefore, it was important to rule out the potential 
interaction effect of current use status. Using bivariate logistic regression analyses, we did 
not detect an interaction effect. Subsequently, 8 variables were still significantly associated 
with craving (at p < .05 for explorative purposes) after correcting for current use status 
(see Table B).
These 8 variables were entered in a logistic regression analysis forward stepwise (Wald) 
procedure (n = 9) with craving yes/no as the dependent variable. Block I consisted of 
current use status (discontinued BZ use yes/no) and block II of the 8 variables. This analysis 
yielded  independent ‘predictor’: POMS depression (see Table A). We attempted to 
confirm this finding in a logistic regression analysis backward stepwise (Wald) procedure, 
with block I the current use status (discontinued BZ use yes/no) and block II the 8 variables. 
Two nonsignificant ‘predictors’ of craving were yielded: POMS subscale depression and 
Dutch Shortened MMPI subscale somatization (see Table B). After omitting depression 
from the list of variables and conducting another logistic regression forward stepwise 
(Wald) procedure analysis as described above, somatization remained as the sole significant 
‘predictor’ of craving (see Table C). Reversed, after omitting somatization from the list of 
variables, depression remained as the sole ‘predictor’ of craving (see Table D).
Further analysis revealed a high and significant correlation between depression and 
somatization (Pearson = 0.5, p < .00). As the influence of block I current use status was 
not significant at α = .00, we cannot pronounce upon its influence on depression, 
respectively, somatization, and craving.
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Table 2A 2 × 2 table of results for craving yes/no and benzodiazepine use yes/no
n = 193 Benzodiazepine use 
No Yes
Craving No n 62 67 n = 129
Row % 48.1 51.9
Column % 77.5 59.3
Table % 32.1 34.7
Yes n 18 46 n = 64
Row % 28.1 71.9
Column % 22.5 40.7
Table % 9.3 23.8
n = 80 n = 113
Table 2B Differences between patients reporting craving (‘cravers’) and patients not reporting craving (‘noncravers’)
‘noncravers’ (n = 129) ‘cravers’ (n = 64)
n/mean %/SD n/mean %/SD significance
Benzodiazepine use 
Discontinued BZ use after letter from GP 62 48.1% 18 28.1% Pearson = 7.006, df = 1 p = .008
Daily dosage, mean (SD) mg diazepam equiv. 5.2 4.6 9.3 11.2 z = -2.075 p = .038b
(n = 67 vs. n = 46)a
Dependence characteristics
BWSQ2 mean (SD) total score
(n = 128 vs n = 63)
5.4 6.3 7.5 7.2 z = -2.200 p = .028
Bendep-SRQ, mean (SD) total score
 Preoccupation (n = 128 vs n = 63) 1.2 1.5 1.8 1.7 z = -2.491 p = .013
 Withdrawal (n = 117 vs n = 61)b .8 1.5 1.7 1.7
Personality characteristics
Dutch Shortened MMPI, mean (SD) total score
 Negativism 11.1 6.8 14.3 8.5 z = -2.598 p = .009c
 Somatization 12.7 7.0 16.6 8.7 z = -2.906 p = .004c
 Psychopathology 2.6 2.8 3.6 3.6 z = -2.053 p = .040
Psychopathology
GHQ-12, mean (SD) total score 1.6 2.9 2.8 3.5 z = -2.799 p = .005c
(n = 128 vs n = 64)
MOS SF-36, mean (SD) (range 0 – 100)
 General health perception 60 21 54 21 z = -2.064 p = .039
 Social functioning 68 20 60 22 z = -2.438 p = .015c
 Role functioning - emotional problem 73 38 60 42 z = -2.209 p = .027c
 Mental health 71 19 63 19 z = -3.406 p = .001c
Mood state
POMS, mean (SD) total score
 Depression 11.7 5.2 14.9 7.3 z = -3.143 p = .002c
 Anger 10.3 4.5 12.3 6.0 z = -2.156 p = .031c
 Fatigue 11.6 5.8 13.4 6.0 z = -2.372 p = .018
 Tension 11.2 5.2 13.1 5.9 z = -2.086 p = .037
a Current BZ users only.
b Left out of the analyses because of missing data and potential selection bias.
c These variables remained significant at p = .05 after correcting for current use status.
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Table 3A Logistic regression forward stepwise (Wald) method
N = 192 Wald df Sig. Exp(B) 95% CI for Exp(B)
Block 1 current use status 4.938 1 0.026 2.121 [1.093 – 4.118]
Block 2 depression 9.350 1 0.002 1.086 [1.030 – 1.144]
Step χ2 = 10.1; df = 1; p = .001
Block χ2 = 10.1; df = 1; p = .001
Model χ2 = 17.5; df = 2; p < .001
Table 3B Logistic regression backward stepwise (Wald) method
N = 192 Wald df Sig. Exp(B) 95% CI for Exp(B)
Block 1 current use status 4.529 1 0.033 2.066 [1.059 – 4.029]
Block 2 somatization 3.015 1 0.082 1.042 [0.995 – 1.091]
depression 3.643 1 0.056 1.059 [0.998 – 1.124]
Step 7:
Step χ2 = -1.2; df = 1; p = .268
Block χ2 = 13.1; df = 2; p = .001
Model χ2 = 20.6; df = 3; p < .001
Table 3C Logistic regression forward stepwise (Wald) method without depression
N = 192 Wald df Sig. Exp(B) 95% CI for Exp(B)
Block 1 current use status 5.252 1 0.022 2.168 [1.118 – 4.201]
Block 2 somatization 8.933 1 0.003 1.064 [1.022 – 1.108]
Step χ2 = 9.4; df = 1; p = .002
Block χ2 = 9.4; df = 1; p = .002
Model χ2 = 16.8; df = 2; p < .001
Table 3D Logistic regression forward stepwise (Wald) method without somatization
N = 192 Wald df Sig. Exp(B) 95% CI for Exp(B)
Block 1 current use status 4.938 1 0.026 2.121 [1.093 – 4.118]
Block 2 depression 9.350 1 0.002 1.086 [1.030 – 1.144]
Step χ2 = 10.1; df = 1; p = .001
Block χ2 = 10.1; df = 1; p = .001
Model χ2 = 17.5; df = 2; p < .001
DISCUSSION
To the best of our knowledge, this is the first study in which the characteristics of a 
population of (former) BZ users reporting BZ craving are described. It is also the first study 
in which clinical variables associated with BZ craving are identified on the basis of cross-
sectional data, gathered through self-report questionnaires in a GP population. 
We found that patients who reported craving differed from patients who did not on 
aspects of 4 of the 5 examined domains (namely, BZ dependence, psychopathology, 
negative mood state, and personality). Patients reporting craving were worse off on all 
4 domains. One apparent characteristic of patients reporting craving was the very high 
tendency to react to psychological strain with physical complaints (somatization) compared 
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with the general Dutch population. If patients had not discontinued their use in the 
previous  months, it was more likely that they reported craving at the time of the 
interview. Among patients who had not discontinued their BZ use and reported craving, 
the average BZ consumption at the time of the interview was higher than among patients 
who had not discontinued but did not report craving. 
The second finding of this study was that self-reported depression and somatization, 
after correcting for BZ use status, were most strongly associated with BZ craving, although 
not statistically significant in the group as a whole. The fact that no single factor emerged 
appeared to be due to the high correlation between somatization, depression, and also 
current BZ use status. However, in the group as a whole, depression seemed to be the major 
contributor to BZ craving. This meant that patients with a negative mood going together 
with a feeling of personal inadequacy, unworthiness, and feelings of guilt have a higher 
chance in reporting craving and vice versa. 
Our findings are in line with some laboratory and field studies that have looked at the 
influence of negative mood state on experienced craving and craving severity. For 
example, Litt et al found that the presence of negative mood states alone appeared to be 
sufficient to elicit desire for alcohol in some subjects, regardless of other cues. Moreover, 
negative affect, both as a dispositional characteristic (e.g., neuroticism) and as a transient 
mood state, seems to play a key role in craving.0 
In explanation of the relationship between somatization and BZ craving, we can turn 
to the cognitive labelling theories (e.g., Refs 4-), which are based on the cognition-arousal 
theory of emotion and applied to drug craving.7 These theories state that craving represents 
the operation of an attributional process whereby physiological reactions are interpreted 
as desires to use the drug.8 However, because of the absence of a formally developed 
cognitive labeling model of dependence, more specifically of craving, there are no 
published studies so far that directly test any predictions derived from such a model. 
We found a strong positive association between negative affect and somatization. 
Watson and Pennebaker9 found negative affect to be associated with a broad range of 
subjective complaints, reflected in high scores on health complaint scales. One can 
hypothesize that patients with negative affect have an elevated bodily awareness, thus 
perceiving physical symptoms more quickly. In the case of BZ dependence or long-term 
use, patients may tend to focus on adverse bodily feelings and label them as a need for a 
BZ. Our study has stressed the need to specify the cognitive labeling model in craving 
research. 
There are some limitations to our study. Because of a cross-sectional design, statements 
about causal relationships between craving and somatization or depression cannot be 
made. Future studies should make clear whether somatization and depression are predictors 
of BZ craving in longitudinal research. Secondly, a high score on the Dutch Shortened 
MMPI subscale somatization can be obtained when a patient has a somatic illness, without 
true somatization. Somatic comorbidity was not taken into account in this study. As the 
sum scores of the MOS SF- physical illness subscales are comparable for patients 
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experiencing craving and patients not experiencing craving, it is unlikely that the very 
high scores on somatization in patients who crave are primarily caused by physical illness. 
Thirdly, although we found somatization and depression as  joint associations with BZ 
craving, odds ratios are low, indicating modest relevance for clinical practice and some 
caution with respect to statements about applicability of existing craving theories and 
comparability to other studies. As our study took place in the patient’s natural environment, 
it is difficult to compare our results to cue-reactivity studies that mainly took place in 
laboratories. Fourthly, the fact that craving could not be explained convincingly may be 
related to the fact that relatively few patients in our population reported BZ craving (%) 
and that the average severity was low. This might be explained by some selection bias as 
patients experiencing higher craving and dependence on BZs may have refused to 
participate in the study. Possibly, more and more severe craving can be found in a (clinical) 
population with more (severe) affective complaints and lower physical and psychological 
well-being. On the other hand, the fact that all our patients expressed the wish to 
discontinue their BZ use makes it a clinically relevant population. Moreover, in contrast to 
some other studies that use single-item questionnaires or visual analogue scales with 
unknown psychometric properties to assess craving (e.g., Ref 0), we used a multi-item 
Rasch homogeneous questionnaire with satisfactory psychometric properties. 
To conclude, our study has made a small but valuable contribution to filling the gap in 
BZ-craving research. As proposed by some researchers, personality may be seen as an 
important explanatory construct in many conceptualizations of craving and may account 
for individually different manifestations of craving.7 Future research should be directed at 
concretizing this relationship between personality and BZ craving.
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Chapter 4
The absence of benzodiazepine
craving in a general practice
benzodiazepine discontinuation trial 
AJJ Mol, RC Oude Voshaar, WJMJ Gorgels, MHM Breteler, AJLM van Balkom,
EH van de Lisdonk, CC Kan, J Mulder & FG Zitman
(Addictive Behaviors 2006;31:211-222)
ABSTRACT
Aim – This study aimed to assess benzodiazepine craving longitudinally and to describe its 
time course by means of the Benzodiazepine Craving Questionnaire (BCQ). 
Setting and participants – Subjects were long-term benzodiazepine users participating in 
a two-part treatment intervention aimed to reduce long-term benzodiazepine use in 
general practice in the Netherlands. 
Measurements – Four repeated measurements of benzodiazepine craving were taken over 
a -month follow-up period. 
Findings – Results indicated that () benzodiazepine craving severity decreased over time, 
() patients still using benzodiazepines experienced significantly more severe craving than 
patients who had quit their use after one of the two interventions, and () the way in which 
patients had attempted to quit did not influence the experienced craving severity over 
time, however, (4) patients who had received additional tapering off, on average, reported 
significantly more severe craving than patients who had only received a letter as an 
incentive to quit. 
Conclusions – Although benzodiazepine craving is prevalent among (former) long-term 
benzodiazepine users during and after discontinuation, craving severity decreases over 
time to negligible proportions. Self-reported craving can be longitudinally monitored and 




‘Craving’ is often regarded as a central phenomenon related to substance dependence. In 
ICD-0, but not in DSM-IV, a ‘strong desire or compulsion’ to use a drug is one of the 
diagnostic criteria for dependence., Craving has been proposed as a factor in maintaining 
continued use or relapse in substance-dependent subjects, although, study results have 
been ambiguous (e.g. -). In a cross-sectional study Bohn et al. found that the scores on the 
Alcohol Urge Questionnaire (AUQ) showed significant negative correlations with the 
duration of abstinence before completing the questionnaire, suggesting a decrease of 
craving over time in abstinent patients.7 Nevertheless, subjects attempting to remain 
abstinent from drugs frequently complain about craving and describe it as having a 
disruptive effect on their daily functioning (e.g. 8 in cocaine abusers). Dependent subjects 
may continue to experience craving years after their last drug use (e.g. 8-0) and regular 
substance users describe experiencing craving even when they are not attempting to 
abstain from drug use (e.g. ,). 
Also, other findings about the longitudinal course of craving are ambiguous. For 
example, Gawin and Kleber8 and also Halikas et al. found craving in cocaine users 
undergoing treatment as a phenomenon to be episodic, waxing and waning over time. 
Others have found relatively stable average craving scores over time. McMillan and 
Gilmore-Thomas, for example, asked opiate addicts on methadone maintenance not 
attempting to remain abstinent to rate their 4-h recall of peak craving scores, as measured 
with a visual analogue scale (VAS), on weekdays during a 4-week study period.4 Although 
average craving scores over time were relatively stable, there were large individual 
differences in subjects’ weekly scores and day-to-day variability within subjects was quite 
high for many subjects. Anton, Moak and Latham, on the other hand, found that all 
alcohol-dependent subgroups (abstinent, ‘slip’ drinking and relapse drinking) showed a 
reduction in scores on the Obsessive Compulsive Drinking Scale (OCDS), assessing the 
craving experience of the previous week during the course of a -week pharmacological 
and cognitive-behavioural treatment trial.5 Although relapsed patients showed an increase 
in the OCDS scores after a period of improvement, scores did not return to baseline prestudy 
levels. Treatment may have allowed these patients to stabilise at a lower level of alcohol 
craving.5 Weddington et al. also found statistically significant decreases in cocaine craving 
during short-term abstinence, as measured with VAS, in a 8-day study among male long-
term cocaine-dependent subjects. West, Hajek and Belcher have found similar results 
among abstinent smokers chewing nicotine gum.7 The frequency of experiencing the urge 
to smoke was highest at 4 h and  week, and then declined over a 4-week period of 
abstinence. However, the average strength of urges did not decline until the fourth week. 
Taking into account the various substances discussed, no clear picture emerges about 
the time course of craving, the association with various use patterns, or its relationship 
with different treatment modalities. 
In benzodiazepine (BZ) research, studies on craving are scarce and have shown 
contradicting results about the occurrence of BZ craving. For example, Lucki, Volpicelli 
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and Schweizer found that treated chronic users of therapeutic doses of BZs after  months 
of abstinence expressed little craving for the drug.8 Whereas, Linden, Bar and Geiselmann 
argued that the refusal of about two-thirds of their general practice patients with long-term 
low-dose BZ dependence to accept a short drug-free intermission, provided evidence for drug-
seeking or craving behaviour, regarding craving to be the equivalent of drug insistence.9 
Recent research has shown that in a sample of Dutch general practice patients about 
% of the long-term BZ users or former users experienced craving. However, the average 
craving severity was limited.0 Patients still using BZs had significantly higher craving 
scores than patients who had recently quit their BZ use. 
Craving has been defined in physiological and behavioural terms, but the assessments 
most widely used in substance abuse research have been subjective.5 In most studies on 
craving simple visual analogue scales to quantify craving or single-item ratings of craving 
of unknown reliability and validity are used. In recent years, however, several multi-item 
craving questionnaires have been developed (e.g. 7,,). One of them is the Benzodiazepine 
Craving Questionnaire (BCQ), a self-report instrument to assess BZ craving. 
The present study is the first study to assess BZ craving longitudinally. Repeated 
measures of the BCQ were taken over a -month study period in a group of long-term BZ 
users participating in a two-part treatment intervention aimed to reduce long-term BZ use. 
Research questions were: () Does the reported craving severity differ among the several 
assessments in time? () Does the overall experienced craving severity differ between 
patients who have quit their BZ use, patients who continue using BZs and those with 
intermittent use patterns, over the study period? () Is the way in which patients have 
attempted to quit their use (of own accord vs. with help from their general practitioner) 
related to the severity of craving they experience over time? 
METHODS
Setting and design 
This study was conducted as part of a large study on the efficacy of a two-part treatment 
intervention that aimed to reduce long-term BZ use in general practice in the Netherlands. 
Participants were known to their general practitioner (GP) to be long-term BZ users. They 
received a letter from their GP (first intervention) with the advice to gradually cut down the 
use of BZs by themselves and if possible to stop using them altogether. The letter also 
informed patients about the drawbacks of long-term BZ use and provided information on 
(how to deal with) withdrawal symptoms. The letter from the GP was used as a pre-selection 
for the second part of the study: a randomised controlled discontinuation trial (second 
intervention), comparing tapering off alone (TO) with tapering off with additional group 
cognitive-behavioural therapy (CBT), and with a control group receiving usual care (UC). 
The study received ethical approval from the University Medical Centre Nijmegen, and 
took place from 998-00. Patients’ responses to the Benzodiazepine Craving Questionnaire 
at four assessments in a -month time span formed the basis of present study. 




We identified long-term BZ users by means of a computerised search for BZ prescriptions 
at 0 general practices. Long-term use was defined as BZ use for at least  months with a 
prescribed amount sufficient for at least 0 days of consumption in accordance with the 
recommended dosage. Exclusion criteria were: current psychiatric treatment, current 
treatment for drug or alcohol dependence, psychosis in medical history, epilepsy, 
insufficient mastery of the Dutch language, or terminal illness. Patients could also be 
excluded specifically on the GPs request, because of severe co-morbidity or for psychosocial 
reasons. Two thousand and four patients met the definition of long-term use and were sent 
a letter by their GP (first intervention). Three months after receipt of the letter with the 
advice to gradually discontinue their BZ use, patients were invited to consult their GP to 
evaluate their current BZ use status and the preceding period. Patients who did not succeed 
in discontinuing on their own accord were asked to participate in the second part of the 
study (discontinuation trial). The tapering off procedure was based on Schweizer et al., 
transferring participants to an equivalent dose of diazepam and reducing dosages by 5% 
a week during four weekly visits to the GP.4 The last visit took place  weeks after the last 
reduction step. GPs were allowed to extend the tapering period if necessary. Group 
cognitive-behavioural therapy consisted of five weekly -h sessions, starting halfway 
through the tapering off period and ending  weeks thereafter. It aimed to support the 
participants during tapering off and to prevent relapse afterwards. The usual care control 
group did not receive any help with BZ reduction and GPs were instructed to give care as 
usual. Patients who did not quit BZ use after the first intervention were randomised for the 
second part of the study in a ratio of :: (TO:CBT:UC) to achieve maximum discriminative 
power between the two experimental groups (TO and CBT). 
Measurements
In this study the course of craving is described by means of four assessments during a 
-month study period. The baseline assessment (T) was carried out after receiving 
informed consent. It took place approximately  months after the start of the first 
intervention (letter from the GP). Three months after the start of the second intervention 
(discontinuation trial) patients received a short-term outcome assessment (T), followed by 
two follow-up assessments (T and T4),  and 8 months, respectively, after the start of the 
discontinuation trial. All four assessments consisted of structured interviews and were 
carried out at the patients’ homes by trained interviewers. 
Measures
BCQ 
The Benzodiazepine Craving Questionnaire (BCQ) was developed by our research group. 
It is a reliable and psychometrically sound Rasch homogeneous self-report questionnaire 
to assess BZ craving in a general practice sample of long-term BZ users. Patients completed 
the original version of the BCQ according to their current experience, by indicating the 
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extent to which they agreed or disagreed with each item on a seven-point Likert-type 
scale. The endpoints of the scale were labelled ‘strongly disagree’ () and ‘strongly agree’ (7). 
For analysis, items of the BCQ were dichotomised between response options four and five 
of the Likert-type scale. Sum scores could range from 0 to 0. 
Other measures
In addition to BZ craving, data were gathered concerning, among others, lifestyle 
characteristics (T only), BZ use, BZ withdrawal symptoms and BZ dependence. Number 
and severity of BZ withdrawal symptoms during discontinuation were assessed with the 
Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ), a 0-item self-report 
questionnaire.5, Severity of BZ dependence was assessed with the Benzodiazepine 
Dependence Self-Report Questionnaire (Bendep-SRQ), a 0-item self-report questionnaire 
consisting of four Rasch homogeneous scales, namely, problematic use, preoccupation, 
lack of compliance and withdrawal.7 All questionnaires show good reliability and validity 
for the Dutch population. Results from the Bendep-SRQ, BWSQ and other variables at first 
assessment are used to describe the study sample. 
Sample size
Of  patients consulting their GP  months after the first intervention, 7 patients 
gave their informed consent to participate in the discontinuation trial. Patients who had 
quit their use of their own accord are also included in this number. They gave informed 
consent for follow-up assessments (as described above). For a graphic representation of the 
patient flow and dropout we refer to Oude Voshaar et al.., Of the 7 patients providing 
informed consent, 8 patients dropped-out before the first assessment, leaving 89 patients 
for the baseline interview. The BCQ was developed shortly after the study had started. Due 
to this delay in the development of the BCQ, 9 patients (of 7) filled in the BCQ at 
baseline. There were no significant differences in background and BZ use characteristics 
between patients who had received the BCQ at baseline and patients who had not or had 
missing BCQ values. Of 9 patients who filled in the BCQ at baseline, 7 completed the 
BCQ at four assessments. The remaining 7 patients had missing BCQ values at one or 
more of these assessments and were left out of the analyses. There were no significant 
differences in background and BZ use characteristics between patients who had completed 
the BCQ at four assessments and patients who had not or had missing values. Oude Voshaar 
et al. have mentioned that some patients allocated to the treatment groups had already 
quit their BZ use before the treatment had started. Since we were particularly interested 
in patients’ actual BZ use behaviour, we did not commit to Intention to Treat analyses 
based on randomisation outcome. We distinguished three main subgroups in our data, 
based on patients’ self-reported BZ use behaviour or ‘pattern’, namely, () BZ users, 
() former users, who had discontinued their BZ use, and () intermittent users, who were 
using and abstinent, respectively, at one assessment, and abstinent and using, respectively, 
at another assessment. These three groups could then be subdivided according to the 
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intervention the patients had received: (A) the letter from the GP only (first intervention) 
and (B) a discontinuation trial additional to the first intervention (second intervention, 
only for patients who had not quit their use after the first intervention). Interim analyses 
showed that BCQ scores did not differ significantly between patients receiving tapering off 
alone and patients receiving tapering off with additional group CBT, irrespective of their 
BZ use status (quit or using). Consequently, these two patient groups (tapering off alone 
and additional group CBT) were combined for the purpose of analysis. For an overview of 
the patient subgroups and numbers, we refer to Table . 
Statistical analysis
To check for baseline differences between the patients who had quit and had not quit their 
use after the letter from the GP, SPSS 0.0.5 (SPSS Inc, Chicago, IL) was used to perform a 
series of univariate t-tests or non-parametric equivalents on socio-demographic and BZ use 
variables. For purpose of analysis, as described above, all 7 subjects were classified into 
six categories based on their actual self-reported BZ use ‘pattern’ ( = quit,  = using, 
 = using intermittently) and the treatment they had received (A = first intervention (letter) 
only, B = additional second intervention (discontinuation trial)). The six categories were: 
(A) patients who only received the first intervention (letter), had quit BZ use thereafter and 
remained abstinent for the duration of the study (n = ); (A) patients who only received 
the first intervention, but continued using BZs thereafter (n = 8); (A) patients who only 
received the first intervention, had quit BZ use at a certain assessment but relapsed at 
another assessment (n = 9); (B) patients who received the additional second intervention 
(discontinuation trial), had quit their BZ use thereafter and remained abstinent for the 
duration of the study (n = 0); (B) patients who received the additional second intervention 
and continued using BZs (n = ); (B) patients who received the additional second 
intervention, had quit BZ use at a certain assessment but relapsed at another (n = ). 
We performed analysis of variance with three factors and first-order interactions. 
Square root transformation was performed to normalise the skewed data. Untransformed 
data are reported in the text. Scheffe’s ratio, a method of post hoc comparison, was 
calculated on the transformed means to identify where the significant differences 
occurred. 
RESULTS
Baseline characteristics of the patients who completed all four assessments (n = 7) are 
presented in Table . The majority of patients was female, elderly, married, had a secondary 
education level and was living on a pension. About 40% of the patients were smokers, 
about half used alcohol, and the majority used caffeine. The average BCQ score indicated 
a relatively low craving severity. On average, BZ dosage did not exceed the therapeutic 
dosage recommended by the WHO. Mean duration of BZ use exceeded 0 years. The overall 
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average severity of BZ dependence in our patient group was low. 
Patients who had not quit their BZ use after the letter from their GP (first intervention) 
had used BZs for a significantly longer period of time (.7 vs. 8. years; Mann–Whitney 
U = 7.5, z = -.4, p = .0), had used BZs in significantly higher daily dosages prior to the 
intervention (7.8 vs. . mg of diazepam equivalents; Mann–Whitney U = 45.5, z = -., 
p = .009), scored significantly higher on three of four BZ dependence severity subscales, 
namely, problematic use (mean total score .7 vs. 0.; Mann– Whitney U = 74.5, z = -4.8, 
p < .000), preoccupation (. vs. 0.5; Mann–Whitney U = 70.0, z = -5.4, p < .000), and 
withdrawal (. vs. 0.8; Mann–Whitney U = 9.5, z = -., p = .00), and had significantly 
higher mean BCQ sum scores (.9 vs. 0.; Mann–Whitney U = .5, z = -.5, p = .0) 
compared to patients who had quit their BZ use after the discontinuation letter. 
Data analysis for the course of BZ craving was based on 7 patients categorised as 
described above. Mean BCQ sum scores for the six subgroups at four assessments are 
shown in Table . There was no significant correlation between reported craving severity 
and BZ dosage. Percentages of patients experiencing BZ craving (BCQ sum score > 0) are 
presented in Table . 
To answer our research questions we performed analysis of variance with three factors 
and first-order interactions. We found a main effect of time on the BCQ sum scores (F,450 = 
9.9, p < .000). There was an overall decrease in BCQ sum scores during the course of the 
study (first research question). Scheffe’s Test revealed a significantly lower mean BCQ sum 
score at the long-term follow-up assessment (T4) 8 months after the start of the second 
intervention, compared to all other assessments. In addition, there was a main effect of BZ 
use ´pattern´ (quit, use, intermittent) on the BCQ sum scores (F,450 = .7, p = .05). On 
average (independent of time and intervention), there was a significant difference in self-
reported craving severity between patients who had quit their BZ use, were still using and 
patients who were using intermittently (second research question). This ´effect of self-
reported behaviour´ could be explained with Scheffe’s Test by a significant difference in 
mean BCQ sum scores between patients who had quit their BZ use and patients who were 
still using BZs, users reporting more severe craving overall. The answer to our third 
research question was negative. There was no interaction between time and intervention, 
i.e., the way in which patients attempted to quit their BZ use (letter only or additional 
discontinuation trial guided by the GP) did not influence the BZ craving they experienced 
during the course of the study. However, on average (independent of time and BZ use 
pattern) there was a significant difference in experienced craving severity between patients 
who only received the letter as an incentive to quit their BZ use and patients who also 
completed the discontinuation trial (main effect of intervention: F,450 = 5., p = .000), 
suggesting that craving does play a role in discontinuing BZ use. Patients who had received 
the additional intervention reported significantly more severe craving (overall mean BCQ 
sum scores .55 vs. .5). Although marginally significant, the effect of BZ use pattern on the 
reported craving differed for each intervention (BZ use pattern * intervention effect: 
F,450 = ., p = .045), in other words, craving reported by the three groups (quit, use, 
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intermittent) had a different course for the patients who received only the letter (first 
intervention) compared to patients who received additional tapering off (second 
intervention). Scheffe’s Test could not be performed on a compound variable. Additional 
analyses showed that the patients still using after the additional second intervention had 
significantly higher BCQ sum scores than patients who had quit after the additional second 
intervention and patients who had already quit or were using intermittently after the first 
intervention. There was no interaction effect between time and BZ use pattern.
Table 1 Baseline characteristics of the study sample 
Total group  (n = 117) 
 n/mean %/SD
Demographic variables
Gender (female) 75 64.1%
Age (years) 62.4 12.0
Marital status
 Steady relationship (incl. married) 72 61.5%
Living alone 40 34.2%
Highest level of education
 Secondary level 81 69.2%
Financial income
 Pension 57 48.7%
Benzodiazepine usage 
Duration of benzodiazepine use (months)a 124.1 100.4
  Quartiles 48.0 – 96.0 – 180.0
Daily dose at first assessment (mg diazepam equivalents)b 7.4 9.5
  Quartiles 2.9 – 5.0 – 8.3
Daily dose 3 months previous to first intervention (mg diazepam equivalents)c 7.0 6.9
  Quartiles 3.0 – 6.0 – 9.0
Craving
Craving severity (BCQ sum score) 1.3 3.5
  Quartiles 0.0 - 0.0 – 1.0
Benzodiazepine dependence characteristics
Dependence severity (Bendep-SRQ sum score)
 Problematic use (n = 115) 1.3 1.2
 Preoccupation (n = 116) 1.6 1.6
 Lack of compliance (n = 117) 0.2 0.7
 Withdrawal (n = 109) 1.3 1.7
Withdrawal symptoms (BWSQ sum score) 6.4 6.7
Substance/drug use
Nicotine use
 Nicotine users 49 41.9%
 Number of cigarettes/day among cigarette smokers (n = 48) 14.2 7.9
Alcohol use
 Drinking alcohol 58 49.6%
 Units of alcohol/week 10.0 8.5
Caffeine use
 Caffeine users 75 64.1%
 Units of caffeine/day 4.4 2.9
a Based on patients who discontinued and did not discontinue their BZ use in the previous 3 months.
b BZ users only.
c Based on recorded consumption extracted from the GP’s clinical database. 
4 The absence of benzodiazepine craving in a general practice benzodiazepine discontinuation trial
Introduction and thesis outline
59
Table 2 Mean BCQ sum score and standard deviation (SD) per patient subgroup, overall and at four
assessments separately 
First intervention only Second intervention (additional)
(letter from GP) (discontinuation trial)*
Self-reported BZ use pattern: Quit Use Intermittent Quit Use Intermittent
N (total = 117): 36 8 19 20 23 11
BCQ sum scores
 Assessment 1** Mean (SD) .33 (.83) 1.13 (2.03) 1.26 (3.89) 1.30 (2.94)# 2.48 (5.37) 2.64 (4.61)
 Assessment 2 Mean (SD) .33 (.72) .25 (.71) .26 (.56) .60 (1.19) 1.78 (3.15) 1.27 (1.79)
 Assessment 3 Mean (SD) .67 (1.93) .13 (.35) .42 (.77) .15 (.37) 1.48 (2.89) 2.55 (5.52)
 Assessment 4 Mean (SD) .28 (1.19) .00 (.00) .00 (.00) .00 (.00) .65 (2.35) .09 (.30)
Overall BCQ sum scores Mean (SD) .24 (.59) .25 (.57) .27 (.65) .30 (.65) .71 (1.05) .68 (1.10)
* This intervention includes only patients who did not quit their BZ use after the first intervention (letter). Before the start 
of the second intervention these patients were randomised either for tapering off alone or for group CBT. In this study the 
usual care control patients were considered as only receiving the first intervention and were placed in the use-group of the 
first intervention. 
** Assessment 1: 3 months after the sending of the letter from the GP (first intervention); assessment 2: 3 months after 
the start of the discontinuation trial; assessment 3: 6 months after the start of the discontinuation trial; assessment 4: 18 
months after the start of the discontinuation trial.
# Since assessment 1 took place before the second intervention these patients were still using BZs at assessment 1.
Table 3 Percentage of patients experiencing craving in each patient subgroup*
First intervention only Second intervention (additional)
(letter from GP) (discontinuation trial)#
Self-reported BZ use pattern: Quit Use Intermittent Quit Use Intermittent
Assessment 1 % 19.4 50.0 31.6 45.0# 47.8 36.4
Assessment 2 % 22.2 12.5 21.1 25.0 52.2 54.5
Assessment 3 % 19.4 12.5 26.3 15.0 52.2 45.5
Assessment 4 % 5.6 0.0 0.0 0.0 13.0 9.1
* BCQ sum score > 0. 
# Since assessment 1 took place before the second intervention these patients were still using BZs at assessment 1.
DISCUSSION
This is the first study in which the long-term course of BZ craving has been described. The 
main findings of our study were: 
1  Over the -month study period the reported craving severity decreased for all patient 
subgroups, regardless of their use status and the intervention they had received (main 
effect of time). At the long-term follow-up assessment 8 months after the start of the 
second intervention, the overall reported craving severity was significantly lower than 
the craving severity reported at earlier assessments for all subgroups, and negligible 
from a clinical point of view. Since patients who had only received the first intervention 
(letter) showed a decrease as well, the decrease in craving severity could not be due to 
the intensive GP guided tapering off (second intervention). Cue-reactivity studies might 
offer an explanation for this finding. Some of these studies have demonstrated that 
Chapter 4 The absence of benzodiazepine craving in a general practice benzodiazepine discontinuation trial
Chapter 1
0
craving can be highly stimulus specific (e.g. 8,9). The two treatment phases of our 
study and the process of abstaining from BZs, focus patients on different kinds of 
discontinuation and withdrawal cues that may lead them to experience craving. At the 
fourth assessment, 8 months after the start of the second intervention, involvement 
from the GP has worn off as might have the patient’s focus on BZ-related (withdrawal) 
cues, everything returning back to normal. Hence, less severe craving is being reported. 
Gritz et al. have found similar decreases over time, although, methods are not 
completely comparable since they asked their subjects to rate how frequently they 
experienced a craving.0 After unaided smoking cessation on a self-determined target 
quit date, frequency of craving (varying from ´never´ through ´constantly´) gradually 
declined from months  to  among subjects who were abstinent at all follow-ups.0 
2  Overall, patients still using BZs reported significantly more severe craving than patients 
who had quit their BZ use during the study (main effect of BZ use pattern). Possibly, 
continued use fosters BZ craving, or vice versa. Bordnick and Schmitz have found 
similar results in cocaine users. Craving intensity during the past week of their 
outpatient treatment and 4-week follow-up was lowest among abstinent subjects and 
highest among subjects with moderate and heavy levels of cocaine use, as measured 
with the visual analogue scale of the Cocaine Craving Scale (CCS). In our study, 
however, there was no significant association between changes in experienced craving 
and changes in BZ dosage. Possibly, the fact that our subjects were all low-dose 
therapeutic BZ users may have accounted for this latter result. 
3  The way in which patients had attempted to quit BZ use (of their own accord only or 
with additional GP guided tapering off with or without additional group CBT) did not 
influence the experienced craving severity over time (there was no interaction effect 
between time and intervention). However, patients who had received the additional 
tapering off intervention, on average, reported significantly more severe craving than 
patients who had only received the letter from the GP (main effect of intervention). In 
addition, patients who had received the additional second intervention but kept on 
using BZs experienced the most severe craving overall. Patients who had quit BZ use 
after the letter (first intervention) experienced the least severe craving. These findings 
suggest that for patients trying to discontinue their BZ use who are reporting more 
severe craving a ´minimal intervention´ alone may not be sufficient and a more 
intensive intervention, such as GP guided tapering off, may be appropriate. We have 
also found that patients who did not quit after the first intervention were more severely 
dependent on their BZs. 
From a methodological point of view our study is in line with Linden et al.9 They found 
that two-thirds of their GP patients with low-dose BZ dependence refused to accept a short 
drug-free intermission, referring to this drug insistence as craving. Kan et al. found that 
40% of all those prescribed BZs in GP were dependent according to DSM-III-R criteria. 
Craving and/or dependence might be an explanation for the relatively low participation 
rate in our study. However, Oude Voshaar et al. have mentioned that success rates for the 
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first intervention were fairly comparable to success rates reported by others. This suggests 
that the patients who responded to the evaluation with the GP  months after sending the 
letter were representative of all patients who received the discontinuation letter with 
respect to BZ use. 
One apparent finding in our study was that, although we found a considerable 
percentage of patients that experienced craving, the severity of the reported craving over 
time was relatively low for all subgroups. The majority of (former) BZ using GP patients 
hardly experienced any craving at all, either during or after their discontinuation process. 
Mol et al. have offered a tentative explanation in their earlier report, referring to the long 
half-lives and slow onset of action of most BZs compared to other substances of abuse in 
which craving is reported to a much higher extent. Since our study sample consisted 
primarily of long-term, low-dose BZ users with the intention to quit, as they expressed this 
intention by giving informed consent to participate in a BZ discontinuation trial, future 
research needs to be conducted to evaluate the nature of BZ craving in untreated BZ users 
and in heavy users. Another possible explanation for the low BCQ scores over time might 
be a potential retest effect of the BCQ. Further longitudinal research, however, needs to 
provide more insight in these matters. 
There is one major strong point compared to most other studies assessing self-reported 
craving. While in most other studies craving is assessed with VAS or single-item rating 
scales of unknown psychometric quality, we have assessed craving using a psychometrically 
sound multi-item questionnaire. 
Since this is only the first study to describe the course of BZ craving longitudinally, one 
should be cautious in generalising and interpreting the results. However, this study further 
supports the notion that BZ craving is prevalent among (former) long-term BZ using GP 
patients, although it seems that severe or intense craving is almost absent.
The BCQ proved to be an instrument sensitive in discriminating the course of craving 
between different subgroups. Although data of other populations, e.g., BZ using psychiatric 
patients and (multi-)drug users, can further substantiate the validity of the BCQ, current 
data have shown that the BCQ is an instrument capable of quantifying craving for BZs 
longitudinally in (former) long-term general practice BZ users. The BCQ sum scores may 
give direction to the advisable treatment intensity, in terms of interference by the GP, when 
a patient is trying to abstain from BZs. 
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ABSTRACT
Aim - This study aims to advance our understanding of craving for benzodiazepines (BZs) 
by comparing two conceptualisations of BZ craving: ) a broad conceptualisation of BZ 
craving, represented by the Benzodiazepine Craving Questionnaire (BCQ), a 0-item Rasch 
homogeneous self-report questionnaire with promising psychometric qualities, and ) a 
narrow conceptualisation, represented by the Benzodiazepine Desire Scale (BDS), three 
single-item Likert-type scales assessing frequency, global and peak intensity of the desire 
for BZs.
Setting and participants - Data were gathered from a sample of  long-term and 
80 former long-term general practice BZ users participating in a large BZ reduction trial in 
general practice in the Netherlands.
Measurements - Sum scores of the BCQ and the BDS were entered in a Maximum Likelihood 
factor analysis together with other (BZ dependence) variables in order to test our hypothesis 
that both conceptualisations of BZ craving would load on one dependence factor different 
from other variables.
Findings - BCQ sum scores loaded on a factor representing negative affect, while BDS sum 
scores loaded on a dependence factor. Low craving intensity, as measured by the BCQ, and 
the selected time frame of craving measurement (current experience versus over the past 
week) are the most likely explanations of these findings in our sample of long-term low 
dose BZ users.
Conclusions - Low craving intensity, as measured with the BCQ, is associated with negative 
affect and reflects the anticipation of positive outcome of BZ use and of relief from 
negative affect or withdrawal. Both conceptualisations of BZ craving contribute to our 




In addiction literature some elaborate and thorough surveys have been published on the 
definitions of craving according to various theoretical models (eg -). There are still some 
unsolved definitional issues, among which is the scope of the craving definition.4,7 While 
some researchers restrict the craving definition to a (strong) desire for use of an addictive 
substance, others use definitions with a broader focus. Both approaches have advantages 
and disadvantages from a theoretical point of view.
Researchers in support of a narrow conceptualisation of craving stick to dictionary 
definitions and have argued to use the term craving only for strong desires to take addictive 
substances. However, there is evidence that a substantial percentage of persons with 
substance use and misuse disorders use the word craving to mean any urge or desire to 
take a drug, even a weak one (e.g. 8,9). Furthermore, there is considerable diversity in the 
specific terms patients use to describe their craving. For example, smokers used significantly 
more affective descriptors than physiological descriptors to characterise their craving and 
significantly fewer synonym words (e.g. urge) than affective, behavioural, and cognitive 
descriptors.0 Researchers in favour of a broad conceptualisation of craving include not 
only desires to use, but also behavioural intentions, lack of control over use, and 
anticipation of positive outcome and of relief from negative affect. 
As a consequence of the many different definitions and conceptualisations of craving, 
craving measurement has been diverse. Sayette and colleagues, among others, evaluated 
different methodological approaches of the measurement of craving. Single-item measures, 
such as visual analogue scales, which often rate craving intensity from none to maximum, 
have face validity.4 However, reliability of a single-item may be low, and unless 
administered with other items sampling the same content area, difficult to estimate.4,, 
Furthermore, single-item ratings may lack the breath required to capture the various 
semantic dimensions used by people to describe their craving.0, 
A broader range of items is advantageous if we take the position that we do not know 
which types of items are the purest indicators of craving. When a broad definition of 
craving is applied, questionnaires designed to assess craving can be categorised as 
presenting craving as a single ‘factor’ or as a multi-factorial construct.4 One of the 
advantages of the use of composite craving scores over single-item scales is that they 
might yield a more reliable estimate of the individual’s craving report. A scale comprised 
of several items addressing desire for an addictive substance as well as other urge-relevant 
categories could provide a substantially more comprehensive representation of the 
semantic organisation of craving report and might also allow for the identification of its 
multidimensional aspects. Moreover, reliability and power can be increased with the use 
of multi-item, relative to single-item, scales. It is also likely that increasing the number of 
items on the self-report measure would increase the reactivity of the measure.4 However, 
the fundamental issue regarding the use of multi-item scales is whether items referring to 
expectancies about the effects of substance use and to the intention to use an addictive 
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substance, can be considered to be distinct components of a broad construct of craving.
Tiffany and colleagues have set the marker for the development of multi-item scales 
that aim to capture a broad range of conceptualisations of craving for different substances, 
by developing the Questionnaire on Smoking Urges (QSU) and the Cocaine Craving 
Questionnaire (CCQ), covering current craving theories as widely as possible.9, Numerous 
questionnaires to assess craving for other substances have been adapted from these 
questionnaires, but most researchers found inconsistent results in terms of number and 
content of factors retained from factor analyses (e.g. Alcohol Craving Questionnaire,5 
Questionnaire of Alcohol Urges and Alcohol Urge Questionnaire, Tobacco Craving 
Questionnaire,7 Marihuana Craving Questionnaire,8 Questionnaire of Cocaine Use,9 and 
recently the Benzodiazepine Craving Questionnaire.0)
Little research has focussed on craving for benzodiazepines (BZs), although these drugs 
have a high prevalence of use in the Western world and there have been many reports on 
their dependence liability.- A psychometrically sound instrument to measure BZ craving 
was lacking until recently. Mol and colleagues have developed the Benzodiazepine Craving 
Questionnaire (BCQ), a unidimensional multi-item questionnaire with promising reliability 
and validity, to measure the construct of craving in long-term BZ users.0 
In this paper the issue concerning the scope of craving is addressed empirically by 
comparing a broad conceptualisation of BZ craving, as represented by the BCQ, and a 
narrow conceptualisation, as represented by the Benzodiazepine Desire Scale (BDS), 
consisting of three one-item Likert-type scales assessing the frequency, global intensity and 
peak intensity of desire for BZs when not using (derived from Schippers and colleagues4). 
To assess the effect of these two distinct conceptualisations, data on their associations with 
other (BZ dependence) related variables were gathered. We hypothesise that in a factor 
analysis the BCQ, the BDS and BZ dependence related variables load on a single factor, 
different from psychopathology, personality factors, quality of life and mood variables. 
METHODS
Setting and design
Patients from a large study on the efficacy of a two-part treatment intervention that aimed 
to reduce long-term BZ use in general practice in the Netherlands received a number of 
questionnaires.5, Patients’ baseline responses to the Benzodiazepine Craving Questionnaire 
(BCQ) formed the basis of the present study.0 The study received ethical approval from the 
Radboud University Nijmegen Medical Centre and took place from 998 to 00.
Subjects and procedure
We identified long-term BZ users by means of a computerised search for BZ prescriptions 
at 0 general practices. Patients were regarded as long-term users when they were using 
BZs for at least three months with a prescribed amount sufficient for at least 0 days of 
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consumption according to the prescription rules. Exclusion criteria and procedures, and 
participation rates are described elsewhere.0 For a graphic representation of the patient 
flow and dropout of the whole study we refer to Oude Voshaar and colleagues and to 
Gorgels and colleagues. 5,
Two hundred and eighty-nine patients participated in the baseline interview. About 
4% had quit their use since receiving a discontinuation letter from their GP (i.e. first 
intervention). The BCQ was developed shortly after the study had started. Due to this 
developmental delay, 9 patients (of 89) filled in the BCQ at baseline. There were no 
significant differences in background and BZ use characteristics between patients who had 
received the BCQ at baseline and patients who had not or had missing BCQ values.0
Measurement
The baseline assessment was carried out after receiving informed consent. It took place 
approximately three months after the start of the first intervention (discontinuation letter).
Measures
Benzodiazepine Craving Questionnaire
The Benzodiazepine Craving Questionnaire (BCQ) was developed by our research group 
and was based on items from the Questionnaire on Smoking Urges (QSU) and the Cocaine 
Craving Questionnaire (CCQ) by Tiffany and colleagues.9, Items reflect five distinct 
conceptualisations of craving: ) desire to use, ) anticipation of positive outcome from BZ 
use, ) anticipation of relief from withdrawal or withdrawal associated negative affect, 
4) intention to use, and 5) lack of control over use. Patients indicated the extent to which 
they agreed or disagreed with each item on a seven-point Likert-type scale according to 
their current experience. The endpoints of the scale were labelled ‘strongly disagree’ () 
and ‘strongly agree’ (7). For analysis, items of the BCQ were dichotomised between response 
options four and five of the Likert-type scale. The BCQ proved to be a 0-item Rasch 
homogeneous self-report questionnaire to assess craving for BZs with promising reliability 
and validity.0
The BCQ was considered to be a good operationalisation of BZ craving since it consisted 
of items reflecting most common craving theories (cognitive, affective and behavioural 
aspects) and it allowed for the measurement of the subjective experience of BZ craving 
independent of the BZ using experience itself. Previous research has shown that the BCQ 
is able to discriminate between patients who have quit their BZ use recently and continuous 
BZ users.0 Furthermore, the BCQ is able to monitor and quantify self-reported craving 
longitudinally.7 Patients completed the original -item version of the questionnaire.
The surplus of Rasch modelling to the ‘classical test theory’ is the justification of the 
use of the sum score as a sufficient statistic for the underlying construct (i.e. the latent 
trait: craving). Although in factor analysis sum scores are often used, different information 
is contained in the item scores, thereby obscuring the associations under investigation (e.g. 
population characteristics are well known confounders of factor structures).8 Furthermore, 
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in questionnaire research continuous single peaked item characteristic curves (ICC’s) may 
occasionally occur, which do not justify the use of sum scores.9
Although the use of questionnaire sum scores is generally accepted in research, this is 
only justified if the Rasch model holds true, as reflected by the goodness of fit statistics R 
and R.0 Rasch homogeneity implicates that the items can be rank ordered according to 
craving intensity or severity on a unidimensional scale, which presents another advantage 
over questionnaire development by means of factor analysis. This means that people who 
admit to an item indicating serious craving problems will also admit to the preceding ‘less 
serious’ items. The extent to which patients crave BZs is reflected by the total score on the 
instrument.
For more detailed information on the assumptions from which the Rasch model can be 
derived, we refer to e.g. Fisher, Kan and colleagues and Van der Ven and Ellis.
Benzodiazepine Desire Scale
Patients also completed three one-item Likert-type scales assessing the frequency, global 
intensity and peak intensity of desire for BZs, respectively, by checking the box of their 
choice. ) Frequency scale: ‘How often during the last week did you experience a desire for 
BZs? (That is the desire for a BZ, while you were not using.)’ Response options ranged from 
 (never) to 0 (constantly); ) Global intensity scale: ‘In general, how intense was your 
desire for BZs during the last week? (That is the desire for a BZ, while you were not using.)’ 
Response options ranged from  (hardly any desire to none) to 0 (very strong desire); 
) Peak intensity scale: ‘Please try to remember the moment during the last week that your 
desire for BZs was most intense. (That is the desire for a BZ, while you were not using.) 
How strong was the desire you felt by then?’ Response options ranged from  (hardly any 
desire or none) to 0 (irresistible desire). This scale has been adopted from Schippers and 
colleagues who used the items for further development of their Obsessive Compulsive 
Drinking Scale.4
Other measures
During the baseline interview data were gathered on BZ use and sociodemographic 
characteristics. Severity of BZ dependence was assessed by means of the 0-item 
Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ). This questionnaire 
consists of four Rasch homogeneous scales with good reliability and validity, namely, 
Problematic use, Preoccupation, Lack of compliance and Withdrawal.,4 Presence and 
severity of psychopathology were assessed with the General Health Questionnaire -item 
version (GHQ-), a measure of psychological wellbeing.5 To assess personality traits we 
used the Dutch Shortened MMPI (NVM) consisting of the sub scales Negativism, 
Somatisation, Shyness, Psychopathology and Extraversion, and mood variables were 
assessed by means of the Profile of Mood States Dutch shortened version (POMS), a 
questionnaire to measure five short-term changeable mood states (Depression, Anger, 
Fatigue, Vigour and Tension).7 We also added a measure of health related quality of life, 
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the Medical Outcome Study Short-Form -item version (MOS SF-). It consists of eight 
domains (physical functioning, social functioning, role limitation due to physical problems, 
role limitation due to emotional problems, mental health, vitality, pain, and general health 
perception) that all have been related to BZ use in the general population. The Dutch 
version of the SF- was previously tested and validated.8,9 All questionnaires show 
satisfactory reliability and validity for the Dutch population. Specially trained interviewers 
interviewed the patients at their homes.
Statistical analysis
All data analyses were conducted using SPSS .0. for windows. To assess the correlation 
between BCQ sum scores and BDS sub scale scores we performed crosstabs procedures 
(Kendall’s tau-c, with correction for nodes). Maximum Likelihood factor analysis, which 
includes a Goodness of fit test for the factor structure found, with Varimax rotation was 
performed on our data. To normalise the skewness of the BCQ data we performed 
logarithmic transformation on the sum scores. Separate Maximum Likelihood analyses 
were performed on data from patients who had quit and had not quit their use, respectively. 
Correlations between the factors found were assessed using crosstabs procedures (Kendall’s 
tau-c, with correction for nodes). To assess the possibility of confounding by the purpose 
of use status (anxiolytic and/or hypnotic) we performed posthoc univariate analyses of 
variance on our data. 
RESULTS
Table  shows the baseline characteristics of our study sample. At the time of the interview, 
4.5% of the total BCQ group (80/9) had quit their use in the three months after receiving 
the discontinuation letter from their GP. The average craving severity as measured with the 
BCQ was low. Concerning BZ dependence, based on the Bendep-SRQ sub scale scores, the 
overall average severity of BZ dependence in our population was low. Average scores on 
the BDS sub scales were also relatively low. Psychopathological dysfunction was relatively 
mild. Based on a cut-off point of / on the General Health Questionnaire -item version, 
% of the patients were classified as ‘psychiatric case’. Sample characteristics have been 
described in more detail elsewhere.0,40 
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Table 1 Baseline characteristics of the total BCQ sample
Total sample  (n = 193) 
 n/mean %/SD
Demographic variables
Age (years) 62.9 12.0
Gender (female) 131 67.9%
Marital status
 Steady relationship (incl. married) 127 65.8%
Living alone 61 31.6%
Highest level of education
 Secondary level 123 63.7%
Financial income
 Pension 90 46.6%
 Profession 27 14.0%
Benzodiazepine usage
Quit after letter with advice to quit benzodiazepine use 80 41.5%
Duration of benzodiazepine use (months)a 129.9 108.2
  Quartiles 48.0 – 96.0 – 186.0
Daily dose (mg diazepam equivalents) (n = 113)b 6.9 8.1
  Quartiles 2.9 – 5.0 – 7.8
Daily dose 3 months previous to first intervention
(mg diazepam equivalents) (n = 190)c
6.7 6.9
  Quartiles 3.0 – 4.5 – 9.0
Benzodiazepine Craving Questionnaire
Craving severity (BCQ sum score) (range 0 - 20) 1.2 3.2
  Quartiles 0.0 – 0.0 – 1.0
Benzodiazepine Desire Scale
 Frequency (n = 190) (range 1 - 10) 3.7 2.9
  Quartiles 1.0 – 3.0 – 6.0
 Global intensity (n = 191) (range 1 - 10) 3.5 3.0
  Quartiles 1.0 – 2.0 – 6.0
 Peak intensity (n = 191) (range 1 - 10) 3.7 3.0
  Quartiles 1.0 – 2.0 – 6.0
 BDS sum score (n = 190) (range 0 - 30) 10.9 8.4
  Quartiles 3.0 – 8.5 – 17.0
Bendep-SRQ
 Problematic use (n = 191) (range 0 - 5) 1.2 1.2
  Quartiles 0.0 – 1.0 – 2.0
 Preoccupation (n = 192) (range 0 - 5) 1.4 1.6
  Quartiles 0.0 – 1.0 – 3.0
 Lack of compliance (n = 192) (range 0 - 5) 0.3 0.7
  Quartiles 0.0 – 0.0 – 0.0
 Withdrawal (n = 178) (range 0 - 5) 1.1 1.6
  Quartiles 0.0 – 0.0 – 2.0
Dutch shortened MMPI
 Negativism 12.2 7.5
 Somatisation 14.0 7.8
 Shyness 10.5 7.1
 Psychopathology 2.9 3.1
 Extraversion 13.2 5.6
Profile Of Mood State
 Depression 12.8 6.2
 Anger 11.0 5.1
Table continues on the next page
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 Table 1 continued n/mean %/SD
 Fatigue 12.2 5.9
 Vigour 15.0 4.7
 Tension 11.8 5.5
Short-Form 36 (range 0-100)
 Physical functioning 68.3 26.0
 Role functioning – physical problem 59.6 40.5
 Pain 64.1 25.1
 General health perception 57.9 21.7
 Vitality 57.6 22.9
 Social functioning 65.5 20.8
 Role functioning – emotional problem 68.9 39.6
 Mental health 68.4 19.4
General Health Questionnaire-12
 Sum score (n = 192) 2.0 3.1
a Based on patients who discontinued and did not discontinue their BZ use in the previous three months.
b BZ users only.
c Based on recorded consumption extracted from the GP’s clinical database. 
Correlations between BCQ sum score and the BDS sub scales were low (Kendall’s tau-c = .7, 
p = .000 for the Frequency scale; Kendall’s tau-c = .4, p = .00 for the Global intensity 
scale; Kendall’s tau-c = ., p = .004 for the Peak intensity scale, respectively). Analysis of 
the internal consistency of the BDS showed a very high reliability coefficient (Cronbach’s 
alpha = .9), suggesting that all three single-item sub scales are measuring the same 
construct, most obviously, desire for BZs. Given this finding, it seemed justified to combine 
the three separate rating scale sum scores into one overall BDS sum score in further 
analyses. The correlation between the BCQ sum score and this BDS sum score was also low 
(Kendall’s tau-c = .5, p = .00). 
Subsequently, we performed Maximum Likelihood factor analysis with Varimax 
rotation on the BCQ sum scores, BDS sum score, Bendep-SRQ sub scale scores, Dutch 
Shortened MMPI sub scale scores, GHQ- sum scores, SF- sub scale scores and POMS 
sub scale scores. Bendep-SRQ sub scale Withdrawal was left out of the analyses due to 
missing data (patients only had to fill in this section if they had attempted to quit their BZ 
use in the past half year). The scree plot recommended a five factor solution with eigen 
values of greater than one, which accounted for 4.5% of the explained variance. However, 
no variables were allocated to the fifth factor. Additional Maximum Likelihood factor 
analysis with the model set to extract four factors with eigen values of greater than one 
accounted for 59.9% of the explained variance. The results of the Goodness of fit Test were 
satisfactory, with Chi-square/df ratio <  (χ = 5.5, df = 8, p = .000).
The BCQ sum score loaded on the first factor together with POMS sub scales Depression, 
Anger and Tension, GHQ- sum score, SF- sub scale Mental health, and Dutch 
Shortened MMPI sub scale Negativism (see table ). This factor was named the ‘negative 
affect-factor’. The second factor consisted of the SF- sub scales (except for sub scales 
Mental health and Role functioning – emotional problem) and was named the ‘(physical) 
quality of life-factor’. Bendep-SRQ sub scales Preoccupation and Problematic use, and the 
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BDS sum score made up the third factor, the ‘dependence-factor’. Factor four (‘extraversion-
factor’) consisted solely of Dutch Shortened MMPI sub scale Extraversion. 
Table 2 Rotated factor matrix of Maximum Likelihood factor analysis with Varimax rotation on a matrix
consisting of scale scores (n = 185)a
Factor: 1 2 3 4
BCQ sum score .34
BDS sum score .58
Bendep-SRQ
 Problematic use .64
 Preoccupation .93
 Lack of complianceb (.41) (.40)
Dutch shortened MMPI
 Negativism .61 (.38)
 Somatisationb (.44) (-.51)
 Shynessb
 Psychopathologyb (.43) (.39)
 Extraversion .50
GHQ-12 sum score (Goldberg) .71 (.31)
SF-36
 Physical functioning .63
 Role functioning – physical problem .79
 Pain .62
 General health perception .64
 Vitality .79 (.36)
 Social functioning (-.32) .64
 Role functioning – emotional problemb (-.38) (.56)




 Fatigueb (.54) (-.55)
 Vigourb (.36) (.45)
 Tension .79
a n = 185 due to missing values in questionnaires other than the BCQ.
Note. The model was set to extract four factors. A variable was assigned to a factor if it loaded .30 or greater on a given 
factor and there was at least .20 difference with another factor. Factor loadings in parenthesis indicate that a variable 
loaded .30 or greater on a factor, but was not allocated to that specific factor.
b Variable could not be allocated to a single factor. Factor loadings of smaller than .30 are not noted in the table.
Correlations between the four factors were rather low (Kendall’s tau-c ranging from -0. 
through 0.7), suggesting that the factors represent distinct domains, indicating good 
factor analysis quality. The negative correlation between the ‘negative affect-factor’ and 
the ‘(physical) quality of life-factor’ was modest (Kendall’s tau-c = -0., p < 0.00). The 
correlation between the ‘negative affect-factor’ and ‘dependence-factor’ was also modest 
(Kendall’s tau-c = 0.7, p < 0.00). There was a very modest correlation between the 
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‘(physical) quality of life-factor’ and the ‘extraversion-factor’ (Kendall’s tau-c = 0.4, 
p = 0.005), and a marginally significant negative correlation between the ‘(physical) 
quality of life-factor’ and the ‘dependence-factor’ (Kendall’s tau-c = -0., p = 0.0). All 
other correlations were non-significant. 
Since patients who were still using BZs had significantly higher craving scores than 
patients who had quit their use recently,0 we repeated the factor analyses on the sub sample 
of non-quitters (n = ) and quitters (n = 80), separately. Due to the small sub sample size 
of quitters and the large number of variables in the factor analysis, no stable factor solution 
was found. Therefore, no interpretation of the factor structure will be presented here. The 
analyses in non-quitters yielded a similar factor structure to the one found for the sample 
as a whole, and accounted for 4.9% of the explained variance. The results of the Goodness 
of fit Test were satisfactory, with Chi-square/df ratio <  (χ = ., df = , p = .009). 
Associations between the factors were also similar to the ones found above. 
Since BCQ assessment took place at daytime and our population included both 
individuals who were using the BZs as an anxiolytic drug and/or as a hypnotic drug, we 
performed a posthoc univariate analysis of variance with purpose of use status as 
independent variable and BCQ sum score as dependent variable. Results showed that BCQ 
sum scores did not differ significantly between the three groups (sedative, hypnotic or 
both) (F, = .95, p = .99). Entering current use status (i.e. quit or still using BZs) as a 
second independent variable did not change these results, nor did correcting for the time 
span between last BZ intake and moment of filling in the BCQ.
DISCUSSION
This study has focussed on the scope of the craving definition, by comparing two distinct 
conceptualisations of craving for BZs, a broad one versus a narrow one. The Benzodiazepine 
Craving Questionnaire (BCQ), a 0-item Rasch homogeneous scale, represented a broad 
craving conceptualisation, with items covering current craving theories as best as possible. 
Three one-item Likert-type scales, comprising the Benzodiazepine Desire Scale (BDS), 
represented a narrow conceptualisation of craving, assessing the frequency, global intensity 
and peak intensity of desire for BZs over a one-week period when not using.
Factor analysis revealed that the structure of our data was best represented by four 
factors, which represent negative affect, (physical) quality of life, dependence and 
extraversion. The BDS together with the sub scales Preoccupation and Problematic use of 
the Bendep-SRQ loaded on the ‘dependence factor’. Although BCQ factor loadings indicated 
some relationship with this factor, the BCQ was designated to the ‘negative affect factor’, 
which refuted our hypothesis. Apparently, in our general practice population of (former) 
long-term, low dose, low dependence BZ users the chosen conceptualisation of craving is 
of importance. 
One possible explanation for our findings is the low intensity of craving in our study 
5 Benzodiazepine craving revised: a comparison of two conceptualisations of benzodiazepine craving
Introduction and thesis outline
75
population, as measured with the BCQ. The items located at the lower end of the Rasch 
rank order of the BCQ reflect anticipation of positive outcome and anticipation of relief 
from withdrawal or negative affect, whereas items at the higher end of the Rasch rank 
order reflect intention to use, desire to use and lack of control.0 This means that in case of 
low craving, as measured with the BCQ, the emphasis is on (cognitive aspects of) affect 
regulation, as one can deduct from the contents of the BCQ items that are confirmed first 
in case of craving. 
Preoccupation, Problematic use and the BDS seem to refer to more obvious dependence 
dynamics. This has been amply demonstrated for the Preoccupation and Problematic use 
sub scales of the Bendep-SRQ.,4 Apparently Peak intensity, Global intensity and Frequency 
of BZ desire are better linked to BZ dependence than to BZ craving as measured with the 
BCQ. As mentioned, items referring to the desire to use BZs are also present in the BCQ, yet 
in the higher regions of the Rasch rank order, indicating higher craving intensity. Patients in 
our population hardly confirmed these BCQ items. Results of the sub sample of patients who 
were still using BZs (non-quitters) were very similar to the results described above, whereas 
an insufficient amount of quitters was included for separate analyses in that group. 
Associations between craving and negative affect have been found in numerous other 
studies for different substances. Childress and colleagues, for example, found that 
hypnotically induced depression produced significant increases in drug craving for opiates 
in 0 male opiate abuse patients.4 They also found a trend for induced anxiety to increase 
self-rated craving. Robbins and colleagues found significant pre- and post-cue correlations 
between craving and POMS sub scales Anger, Confusion, Depression, Fatigue, Tension and 
Vigour (the latter was negatively correlated), with the highest correlation found for 
Depression in a sample of 8 cocaine-dependent outpatients.4 Rabois and Haaga found 
that in their sample of 89 regular light smokers who were not necessarily trying to quit or 
interested in quitting, sad mood predicted higher temptation to smoke.4 Singleton and 
colleagues also found that the subjective experience of craving in nicotine users had a 
negative emotional valence.44 They found a pattern of increased negative mood, decreased 
positive mood and increased craving under different craving conditions, as realised 
through imagery scripts. Based on results from other craving studies one can hypothesise 
that negative mood states can become conditioned stimuli capable of triggering craving 
(see also4). Based on the importance of cognitive aspects of craving in our study, one can 
also hypothesise that patients might have attributed the negative affect to craving 
(e.g. I feel miserable because I have no BZs).
The fact that our patients experience some ‘desire’ for BZs as indicated on the BDS, but 
not on the BCQ, might be explained by the differences in the inquired time frame of the 
craving experience: patients had to indicate their current feelings on the BCQ, whereas for 
the BDS patients had to evaluate their feelings over the past week when not using. 
Questions referring to prior craving experience are subject to recall bias, potentially 
leading to overestimation of the amount of craving.45,4 This might account for the 
discrepancies found between the BCQ and BDS in current study.
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In addition to the difference in time frame of craving measurement between both craving 
measures, some methodological issues must be addressed. Patients used BZs for different 
purposes: anxiolytic, hypnotic or both. Although purpose of use status could have 
confounded BZ craving severity, post-hoc analyses on the BCQ did not show differences in 
craving between hypnotic users and anxiolytic users. Furthermore, our results are 
representative for the majority of long-term BZ users, i.e. general practice patients of older 
age and female sex with low-dose use and low dependence (cf ). Consequently, in other 
populations, such as multiple drug users and BZ dependent psychiatric patients, the 
outcome might be significantly different in terms of factor structure. We hypothesise that 
these patients would confirm the items in the higher regions of the Rasch rank ordering 
and thus experience more severe craving in a sense of desire, intention to use and possible 
lack of control.
The measurement of craving has received considerable research attention over the 
years. Unfortunately, only a few studies have assessed the psychometric properties of self-
report instruments. In view of the importance of anticipated outcomes in almost all 
theoretical accounts of craving, it may be preferable for research purposes to use 
instruments that provide measures of anticipated outcomes for use, such as the BCQ, in 
addition to the pure measure of desire to use.47 Nonetheless, our study clearly shows that 
using multiple measures of craving contributes to our understanding of the significance 
and meaning of this construct in BZ use. Based on findings from the present study, future 
research should be directed at achieving a more precise understanding of negative affect 
(both as state and trait manifestations) as a possible cue for BZ craving. If certain mood 
states are modulators of BZ craving they demand treatment attention.
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Chapter 6
The role of craving in
relapse after discontinuation of
long-term benzodiazepine use
AJJ Mol, RC Oude Voshaar, WJMJ Gorgels, MHM Breteler, AJLM van Balkom,
EH van de Lisdonk, CC Kan & FG Zitman
(In press: Journal of Clinical Psychiatry)
ABSTRACT 
Objective – Craving for benzodiazepines has never been examined as a factor of relapse 
after successful benzodiazepine discontinuation. In this study, we examined the predictive 
value of craving on benzodiazepine relapse.
Methods – A stepped-care intervention trial aimed to discontinue long-term benzodiazepine 
use in general practice. The first step was the sending of a letter to users with the advice to 
gradually quit their use by themselves (i.e. minimal intervention). The second step, a 
supervised tapering off programme, was offered to those unable to discontinue by 
themselves. Craving was assessed by means of the Benzodiazepine Craving Questionnaire 
(BCQ). Multiple Cox-regression analyses were performed to examine the effect of craving 
on subsequent relapse during a 5-month follow-up period in patients who had successfully 
quit their benzodiazepine use by themselves after the minimal intervention (n = 79) and in 
those patients who had successfully quit after the supervised tapering off programme 
n = 45). Data were collected from August 998 to December 00.
Results – Thirty-five (44%) and 4 (5%) patients had relapsed after the minimal intervention 
and tapering off programme, respectively. Patients able to quit by themselves hardly 
experienced any craving. In this sample, craving was not related to relapse (p = 0.8). In 
patients who needed an additional supervised tapering off programme, higher craving 
scores were significantly related to relapse (HR = . [95% CI: .0 – .54], p = 0.09), 
when corrected for benzodiazepine characteristics, psychopathology and personality 
characteristics.
Conclusion – Craving is an independent factor of subsequent relapse after successful 
benzodiazepine discontinuation in long-term benzodiazepine users who are not able to 




Craving is generally considered as an important variable in substance dependence. 
Empirical results, however, are not consistent suggesting that craving is neither sufficient 
nor necessary for continued use or relapse to the use of addictive substances (for an 
overview see e.g.). The concept of craving has been studied frequently in substance 
dependence for various substances, but hardly in case of benzodiazepine use. Although 
benzodiazepines have the potential to cause all aspects of dependence even in low dosages, 
only one study has examined the prevalence of benzodiazepine dependence according to 
ICD-0 and DSM-III-R criteria. That study has found that approximately half of all 
benzodiazepine users in general practice met the criteria for benzodiazepine dependence. 
Recently, the concept of craving for benzodiazepines has been examined within a 
benzodiazepine discontinuation project,4,5 which has resulted in the development of the 
Benzodiazepine Craving Questionnaire (BCQ). Up till now, benzodiazepine craving has 
never been examined prospectively in relation to benzodiazepine relapse after successful 
benzodiazepine discontinuation.
Several factors, e.g. benzodiazepine dosage, dependence characteristics, psychopathology 
and personality, have been related to successful benzodiazepine discontinuation,7- but 
almost exclusively concern short-term outcome programmes. Although  out of  patients 
successfully quit their use by means of these programmes, relatively high relapse rates 
have been reported,, stressing the need to identify patients at risk for relapse. The only 
two studies that have evaluated relapse after a supervised benzodiazepine tapering off 
programme have found treatment condition (cognitive-behaviour therapy for insomnia, a 
supervised medication taper program, or a combined approach), end of treatment insomnia 
severity and psychological distress, respectively, self-efficacy in coping without 
benzodiazepines, as predictors of relapse.,4 Two other papers have examined predictors 
of relapse in benzodiazepine users who had quit their use by themselves after receiving a 
letter containing the advice to discontinue their use. Baseline characteristics that predicted 
relapse in this population were a higher dosage, use of more than one benzodiazepine, 
lower general health perception, and hypnotic type benzodiazepine.5,
This study was conducted to test the hypotheses that craving is an independent predictor 
of relapse in long-term benzodiazepine users who successfully quit their use after 
) a minimal intervention, respectively, ) after an additional supervised benzodiazepine 
tapering off programme in general practice.
6 The role of craving in relapse after discontinuation of long-term benzodiazepine use
Introduction and thesis outline
8
METHODS
Study design and participants
This study was conducted as part of a larger study on the efficacy of a stepped-care model 
aimed to reduce long-term benzodiazepine use in general practice in the Netherlands. 
Participants were long-term benzodiazepine using general practice patients from 0 general 
practices with 55 general practitioners (GPs). Long-term users were selected on the basis of 
the following criteria: () having received benzodiazepine prescriptions for at least 
 months, and () having received prescriptions in an amount sufficient for at least 0 days 
in the  months prior to this study. Patients were excluded if benzodiazepine discontinuation 
could have a negative impact on their additional psychiatric treatment or underlying 
(major psychiatric) disorder (e.g. bipolar disorder, schizophrenia). For details on the 
exclusion criteria see figure . 
Figure 1 Flowchart patient recruitment
Excluded, total n = 960, among which
 - current psychiatric treatment (n = 281)
  - current treatment for drug or alcohol dependence (n = 82)
 - psychosis in medical history (n = 80)
 - epilepsy (n = 53)
 - insufficient mastery of the Dutch language (n = 59)
 - suffering from a terminal illness (n = 26)
 - at instigation of the general practitioner (n = 379)
Received discontinuation letter
N = 2004
Refused informed consent, n = 176
No BCQ available, n = 29
Recorded consumption missing, n = 1
Refused to discontinue, n = 20
Discontinued before start RCT, n = 23
Usual Care control group, n = 34
Failed to discontinue, n = 43
Dropped-out before outcome assessment, n = 5
BCQ with missing values, n = 10
Eligible for RCT (continued BZ use)
N = 1036
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The first step of the study was a minimal intervention strategy, i.e. a letter from the general 
practitioner (GP) with the advice to discontinue benzodiazepine use by themselves. Patients 
who had successfully quit their benzodiazepine use by themselves after receiving this 
letter, were the first group of interest for the present study. Patients who had continued 
benzodiazepine consumption after this intervention were approached to participate 
in the consecutive, more intensive step, i.e. a randomised controlled benzodiazepine 
discontinuation trial with three conditions: ) tapering off alone, ) tapering off with 
simultaneous group cognitive-behaviour therapy and ) a usual care control group. 
Patients who had successfully quit their usage after participation in one of the two active 
conditions of this randomised controlled trial were the second group of interest for the 
present study. Since patients in both active treatment conditions were equally successful 
with similar rates of relapse, this group was treated as one cohort., Written informed 
consent was obtained from all participants after full explanation of the study procedures.
The study received ethical approval from the Radboud University Nijmegen Medical 
Centre and was carried out between August 998 and December 00. It has been described 
in detail previously.4,5 Figure  presents the recruitment process for the present study.
Measurements
The use of benzodiazepines and other prescribed drugs was monitored prospectively in the 
GPs medical records for a 5-month follow-up period. Drug prescription data were 
extracted on patient level from the GPs computerized medical records. In the Netherlands 
every patient is linked to only one GP who collects all medical information, including the 
use of prescribed medication. Moreover, more than 90% of the GPs use commercially 
available electronic medical dossiers enabling reliable data collection. Relapse was defined 
as receiving a benzodiazepine prescription during follow-up (for details, see).
In addition to the computerized benzodiazepine prescription records, we assessed 
patients immediately after they had quit their benzodiazepine use after the first, 
respectively, the second intervention. 
The primary variable of interest, benzodiazepine craving, was assessed by means of the 
Benzodiazepine Craving Questionnaire (BCQ), developed by our research group. The BCQ 
is a unidimensional 0-item self-report questionnaire with good psychometric properties 
to assess benzodiazepine craving according to the patients’ current experience. Sum scores 
can range from 0 to 0. In a previous report on the BCQ it was shown that patients who 
reported craving (sum scores of greater than zero) differed significantly from patients who 
did not report craving on the BCQ, concerning aspects of dependence severity, 
psychopathology, negative mood state, and personality.7 
Additionally, we assessed the use of caffeine, nicotine, and alcohol, and the following 
self-report questionnaires were administered: severity of benzodiazepine dependence 
(Bendep-SRQ: Benzodiazepine Dependence Self-Report Questionnaire),8,9 psychological 
well-being (GHQ-: General Health Questionnaire  item version),0 mood (POMS: 
Profile of Mood States), quality of life (MOS SF-: Medical Outcome Studies short-
form),, and personality characteristics (NVM: Dutch shortened MMPI).4
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Analyses
Both patient groups of interest, i.e. the group that had successfully quit after the first minimal 
intervention and the group that had quit after the additional supervised tapering off 
programme, were analysed separately. Since the BCQ sum scores were quite low, we first 
explored the data by comparing patients who did not report any craving (BCQ sum score = 0) 
and patients who reported craving to some extent (BCQ sum score ≥ ), using cross-tabs.
Predictors of relapse were analyzed separately by means of Cox-regression analyses 
with time to relapse as the dependent variable and each of the following as the independent 
variable: BCQ sum score (range 0 - 0), daily benzodiazepine dosage (dichotomised at 
0 mg diazepam equivalent), half-life (dichotomised at 4 hours), potency (presence of a 
4-aryl group), hypnotic or anxiolytic use (dummy variable defined as self-reported 
(a) night-time use, (b) daytime use, (c) use at both night-time and daytime), use of 
antidepressants, use of pain medication, use of psychotropic drugs other than 
benzodiazepines, and finally, all variables measured at the baseline assessment. Patients 
lost to follow-up were analysed until the moment of loss to follow-up as censored 
observations. After the univariate Cox-regression analyses, variables with a Wald 
χ statistic of p < 0.5 were entered into a multivariate Cox regression model using a 
forward, conditional procedure. Crude and adjusted hazard ratios (HR) with 95% confidence 
intervals (95% CI) are reported. A p-value of < 0.05 was considered significant in the final 
model. The output of the Cox-regression analysis was checked for instability by influential 
cases and for violation of the proportional hazards assumption. We used SPSS version 0.0 
(SPSS Inc, Chicago, IL) to perform all analyses.
RESULTS
First intervention: discontinuation letter
Seventy-nine patients who had quit after the discontinuation letter were included in the 
present analyses (see figure ). The mean (SD) age of these patients was  () years old 
and 8% was female. Patients used benzodiazepines for a mean (SD) duration of .9 (7.) 
years in a mean (SD) daily dosage of 5.9 (.0) mg diazepam equivalent. 
The mean (SD) BCQ sum score was 0.5 (.0) (quartiles: 0 – 0 – 0, range 0 - ). Eighteen 
patients reported craving to some extent, as indicated by a BCQ sum score of greater than 
zero. The proportion of relapse did not differ between patients with and without craving 
(7/ (44%) versus 8/8 (44%), p = 0.99). As shown in table , the BCQ sum score had no 
predictive value with respect to relapse in the univariate nor in the multivariate Cox-
regression analyses (p = 0.8, respectively, p = 0.7).
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Table 1 Univariate and independent predictors of relapse in successful quitters after a minimal intervention
Univariatea Multivariateb
Variables Hazard Ratio [95% CI] p-value Hazard Ratio [95% CI] p-value
BCQc sum score (range 0 – 20) 0.82  [0.55 – 1.20] .82 0.93  [0.65 – 1.32] .67
Benzodiazepine dosage (> 10mg) 3.00  [1.43 – 6.27] .004 4.17  [1.87 – 9.30] < .001
Duration of BZ use (years) 0.04  [0.00 – 0.77] .042
Age (years) 1.03  [1.00 – 1.06] .055
Stable relationship 0.49  [0.25 – 0.96] .036
Living alone 1.93  [0.98 – 3.70] .057
Use of alcohol 1.83  [0.92 – 3.58] .083
Vitality (SF-36 sub scale) 0.99  [0.97 – 1.00] .054
Extraversion (NVM sub scale) 0.94  [0.88 – 1.01] .004 0.92  [0.87 – 0.98] .008
Model: χ2 = 17.2; df = 3; p < 0.001
a Only independent variables that had p-values of less than 0.15 in the univariate regression analyses are shown in the table.
b All univariate predictors were entered in the first block, using a forward Wald procedure, where after the BCQ score was 
added in the second block.
c Benzodiazepine Craving Questionnaire
Second intervention: supervised tapering off
Of the 80 patients who participated in the randomised controlled trial, 0 were of interest, 
as they successfully discontinued their benzodiazepine use with the aid of the tapering off 
protocol. Forty-five patients were included for analyses (5 patients withdrew from 
treatment, and 0 patients provided incomplete data (see figure )). In- and excluded 
patients were comparable with respect to age, gender, benzodiazepine dosage before the 
start of tapering off, and duration of use (all p-values > 0.8). The mean (SD) age of the 
45 participants was  () years old and 7% was female. Patients used benzodiazepines 
for a mean (SD) duration of .8 (9.5) years in a mean (SD) daily dosage of 7.5 (4.7) mg 
diazepam equivalent.
The mean (SD) BCQ sum score was . (.9) (quartiles: 0 – 0 – , range 0 - 8). Nineteen 
patients reported craving to some extent as indicated by a BCQ sum score of greater than 
zero. The proportion of relapse was higher in patients reporting craving versus patients 
reporting no craving at all (/9 (8%) versus / (4%), which approached significance 
(p = 0.08)). Figure  shows the survival curves for relapse to benzodiazepine use for cravers 
(BCQ sum score of  or higher) and non-cravers (BCQ sum score of zero) separately. When 
corrected for time till relapse by a Cox-regression analysis, the BCQ sum score (range 0 - 8) 
was significantly related to relapse (HR = .0 [95% CI: .07 – .], p = 0.00). As this result 
was influenced by one outlier (BCQ sum score = 8, relapse into benzodiazepine use after 
 days), the sum score of this outlier was corrected for on the basis of z-scores. Allocation 
of a z-score of  yielded a corrected sum score of 0 on the BCQ, thus decreasing the outlier 
effect yet maintaining the extreme position in the data. The hazard ratio of the BCQ sum 
score remained significant after this correction (see table : HR = .8 [95% CI: .07 - .55], 
p = 0.009). After correction for other significant independent predictors of relapse, the BCQ 
sum score still accounted for unique variance (HR = . [95% CI: .0 – .54], p = 0.09).
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Figure 2 Survival time untill relapse after successful discontinuation
Table 2 Univariate and independent predictors of relapse in successful quitters after a tapering off programme
Univariatea Multivariateb
Variables Hazard Ratio [95% CI] p-value Hazard Ratio [95% CI] p-value
BCQc sum score (range 0 – 20) 1.28  [1.07 – 1.55] .009 1.26  [1.02 – 1.54] .029
Age (years) 1.04  [1.00 – 1.07] .063 1.06  [1.02 – 1.11] .007
Insurance status (1 = private; 0 = NHS) 0.43  [0.18 – 1.06] .068 0.30  [0.11 – 0.77] .013
Duration of benzodiazepine use (years) 1.00  [1.00 – 1.01] .080
Problematic use (Bendep-SRQ sub scale) 1.37  [0.92 – 2.06] .125
Preoccupation (Bendep-SRQ sub scale) 1.32  [0.96 – 1.80] .085
Lack of compliance (Bendep-SRQ sub scale) 6.42  [1.42 – 29.1] .016 8.25  [1.71 – 39.9] .009
Withdrawal (Bendep-SRQ sub scale) 1.25  [0.97 – 1.60] .083
Pain (SF-36 sub scale) 0.86  [0.74 – 1.00] .055
General health perception (SF-36 sub scale) 0.91  [0.84 – 1.00] .039
Vitality (SF-36 sub scale) 0.92  [0.85 – 1.00] .039
Mental health (SF-36 sub scale) 0.91  [0.85 – 0.98] .017
GHQ-12 sum score 1.15  [0.98 – 1.35] .091
Anger (POMS sub scale) 1.06  [0.99 – 1.13] .099
Fatigue (POMS sub scale) 1.06  [1.00 – 1.12] .044
Vigor (POMS sub scale) 0.93  [0.86 – 1.00] .048
Shyness (NVM sub scale) 0.95  [0.89 – 1.01] .080
Extraversion (NVM sub scale) 1.08  [1.00 – 1.16] .039
Model: χ2 = 22.6; df = 4; p < 0.001
a Only the independent variables that had p-values of less than 0.15 in the univariate regression analyses are shown in the table.
b All univariate predictors were entered in the first block, using a forward Wald procedure, where after the BCQ score was 
added in the second block.
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This is the first study examining the effect of benzodiazepine craving on relapse after 
successful discontinuation. We found different results in our two groups of interest: in 
patients able to discontinue on their own after receiving a discontinuation letter, we did 
not detect any effect of craving on subsequent relapse. However, in long-term 
benzodiazepine users who needed additional treatment to discontinue successfully, i.e. a 
supervised tapering off protocol, a higher extent of craving, as measured with the 
Benzodiazepine Craving Questionnaire (BCQ), predicted relapse during a 5-month follow-
up period, independent of other predictors. This differential effect of craving was probably 
best explained by population characteristics. Patients who were able to discontinue 
relatively easy, i.e. with the aid of a discontinuation letter, probably lacked the significant 
influence of dependence characteristics and therefore hardly experienced any craving, as 
supported by the low BCQ sum scores and lack of variance herein. 
Interpretation of our results is hampered by the lack of previous benzodiazepine relapse 
studies to compare with. To our knowledge, only two studies specifically examined relapse 
after successful discontinuation by means of a supervised benzodiazepine tapering off 
programme, but none of them included measures of benzodiazepine craving.,4 The study 
of Morin et al was limited to long-term benzodiazepine users suffering from insomnia 
(n = 47). They found end of treatment insomnia severity and psychological distress as 
predictors of relapse, analogous to univariate effects of mental health characteristics in 
our study (subscale mental health of the SF-, respectively, anger, fatigue, and vigour of 
the POMS). However, in our multivariate model, these characteristics lost significance after 
correction for age, socioeconomic status and benzodiazepine dependence severity (subscale 
lack of compliance of the Bendep-SRQ) of which the latter variable had not been included 
by Morin et al. The other study reported a negative association between self-efficacy in 
coping without benzodiazepine use and relapse after successful supervised tapering off, 
based on a small study of  patients with anxiety or insomnia of which  had relapsed at 
-months follow-up.4 In various studies on smoking, higher levels of self-efficacy are 
consistently associated with decreased craving (e.g.5,), whereby findings from O’Conner 
et al4 appear to be in line with our findings. Similar to our results, Morin et al and 
O’Connor et al4 did not find an effect of benzodiazepine dosage, suggesting that this 
variable is only important for achieving successful discontinuation after supervised 
tapering off but not in subsequent relapse. 
Since the study was conducted in primary care, mainly elderly low-dose users were 
included, thereby limiting generalisation to high-dose benzodiazepine users. In previous 
reports on the second step of this study, i.e. the randomised controlled trial, we have 
shown that the participants were representative of all long-term benzodiazepine users 
unable to discontinue by themselves after receiving a discontinuation letter, with respect 
to age, gender, and benzodiazepine dosage (for details and discussion see4). Nevertheless, 
even if our recruitment process has led to significant selection bias, this bias is probably 
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comparable to clinical practice in which most likely only motivated patients will be 
referred for benzodiazepine discontinuation treatment.
The concept of low-dose benzodiazepine dependence has been criticised by some 
researchers, mainly for two reasons: (i) the number of benzodiazepine users who escalate 
their dosage beyond therapeutic levels is low,7 and (ii) long-term, low-dose benzodiazepine 
usage is considered as ‘normal physical dependence’ necessary for the long-term treatment 
of chronic anxiety and should therefore not be considered abuse or addiction.8 Advocates 
of the concept of low-dose benzodiazepine dependence emphasise that (a) the withdrawal 
syndrome for benzodiazepine includes unique symptoms that can be distinguished from 
rebound anxiety,9 that (b) withdrawal symptoms are identical for low-dose and high-dose 
users,0 and finally, (c) that approximately half of all low-dose users fulfil DSM-III-R 
criteria for dependence. Our results contribute to these latter arguments by showing that 
craving, a concept specifically associated with the use of addictive substances, predicts 
relapse after successful discontinuation of low-dose benzodiazepine usage. 
Our findings point to a potentially important role for craving in subsequent relapse 
after successful benzodiazepine discontinuation, but only for the subgroup of low-dose 
benzodiazepine users who need specific treatment for benzodiazepine discontinuation in 
clinical practice. If these results hold true in subsequent studies, they should guide relapse 
prevention programmes, including treatment elements with a focus on (coping with) 
craving experiences. 
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The focus of this thesis has been on the development and initial validation of the 
Benzodiazepine Craving Questionnaire (BCQ). The BCQ was developed within a population 
of long-term and former long-term general practice benzodiazepine users participating in 
a large benzodiazepine discontinuation trial in the Netherlands. With this study we 
have made an attempt to fill a gap in craving research and we have contributed to the 
understanding of craving for benzodiazepines.
In this chapter we address the strengths and limitations of this study on the basis of the 
results and present the major conclusions of this thesis. Adaptations and ideas for further 
research are suggested in order to further substantiate the psychometric properties of the 
BCQ. Finally, some potential clinical implications are discussed.
STRENGTHS AND LIMITATIONS
The results of our study have already been discussed in the previous chapters of this thesis. 
Below, the (methodological) strengths and limitations of our study are addressed, together 
with their implications for the interpretation of the results.
Study participants: generalisability of our results
The development of the BCQ took place within the Benzoredux project, a two-part 
treatment intervention aimed at reducing long-term benzodiazepine use in general 
practice. Patients from rural and urban general practices were selected a priori by means of 
a computerised search with benzodiazepine use for more than three months as the principal 
criterion. Patients also had to meet our other inclusion criteria. The attrition rate was fairly 
high for both treatment interventions (about 5% of the patients turned down the invitation 
to evaluate their cut down attempt after the discontinuation letter from their general 
practitioner, and only 7% took part in the tapering off trial, respectively)., Although 
high-dose benzodiazepine users were not excluded beforehand, the average benzodiazepine 
dose levels were rather low and within the therapeutic range. Nevertheless, this low 
participation rate was comparable with another Dutch general practice study. For users of 
high dosages of benzodiazepines any intervention may appear aversive. These users 
possibly are not ready to undertake action to change at all.4 Stages of change research into 
other substances of abuse has suggested that attrition and drop-out rates are significantly 
higher for users who are not ready to change their behaviour than for users who are.5-7 In 
that respect the results of our study seem to be in line with previous work.
We also expect that, among others, dependence might have played a role in the low 
participation rate and the use of low benzodiazepine dosages among participants, 
implicating that the more severely dependent patients possibly refused to take part in our 
study. Research has shown that 40% of all benzodiazepine users in general practice meet 
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dependence criteria according to DSM-III-R.8 This suggestion was supported by our own 
Bendep-SRQ cross-validation study, although Bendep-SRQ subscale scores were 
significantly lower in our study (which supports the hypothesis that the more severely 
dependent patients refused to participate).9 In addition, craving might have played a role 
as well. Linden et al.0 labelled the refusal of two-thirds of their long-term low-dose 
benzodiazepine users to take a short drug-free intermission as craving. Nonetheless, our 
findings are of interest for and reflect daily clinical practice since our study selectively 
recruited those patients who were prepared to try to discontinue their usage, whereas the 
non-participants probably will never be treated in day-to-day practice to reduce their 
benzodiazepine use.
The abovementioned has influenced the degree of generalisability of our BCQ data. 
Ideally, one would draw a random, stratified or a multi-stage sample from a ‘sampled 
population’ in order to get a good enough representation of the population. For 
administrative and logistic reasons, it was not possible to get the most optimal sample for 
the development of the BCQ. However, the choice to develop the BCQ within this Benzoredux 
population was acceptable because of the existing lack of research into benzodiazepine 
craving and the fact that we applied population independent Rasch analyses. Furthermore, 
the Benzoredux project aimed to include as many benzodiazepine users as possible and it 
was a minimal extra strain for participants to fill in the BCQ. The abovementioned, however, 
calls for replication of our study in a comparable, but less selective sample. 
Development of the BCQ
Rasch scaling model
The design of the Benzoredux project implicated the use of (self-report) questionnaires. 
There was no valid benzodiazepine craving instrument available, so we had to develop one 
and examine its psychometric properties. 
Questionnaires are usually developed in accordance with ‘classical test theory’. One of 
the major problems with classical test theory is its population dependence. Drawbacks of 
scale construction by means of factor analysis have been described in chapters  and 5 
(e.g. population characteristics are well known confounders of factor structures). 
Furthermore, common questionnaires use sum scores as an indicator of craving severity, 
however, the conceptual homogeneity of the items in a scale is not addressed by the 
classical test theory. 
‘Item response theory’ or ’latent trait theory’, however, addresses both issues. This 
theory was developed without any reference to any population (i.e. it is population 
independent) and it has provided a theoretical framework to assess the consistency between 
the latent trait, i.e. the underlying construct, and the specific responses on a set of items. 
The main reason for choosing a model based on item response theory (i.c. Rasch scaling 
model) in this study, therefore, was to be able to properly use the sum scores of the BCQ as 
a sufficient statistic for the underlying construct, i.e. craving. 
Although the advantages of the item response theory over classical test theory have been 
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outlined (see chapters  and 5 and  for an elaboration on Rasch analysis) there are some 
limitations to the use of the Rasch scaling model caused by the limitations of the computer 
program used to analyse the data, the Rasch Scaling Computer Program (RSP). This 
program requires dichotomisation of the BCQ items, implicating the loss of valuable 
information contained in the data, possibly causing reduction in scale discriminability. 
Theories on the polytomous Rasch model have been described, in which the sum score 
of the original item scores are a sufficient parameter for the subject parameter. Computerised 
programs that can be applied on polytomous items became available in the last few years. 
There are other modern measurement models available that are based on item response 
theory and do not require dichotomisation of the data, e.g. the nonparametric Mokken 
models. Some authors advise to use not just one model for analysing data but to use 
several, because of the different measurement properties and different methods for data 
analysis.4 Compared with the Mokken models, the Rasch scaling model is best applied 
when the number of items is rather high (e.g. greater than 0).5 Furthermore, the Rasch 
scaling model is more restrictive. In other words, it is easier to meet the assumptions of a 
nonparametric model than it is to meet those of a parametric model. The Rasch scaling 
model gives more profound information about scale and item properties. Only with 
parametric information about the latent trait and the responses of the subjects to items it 
is possible to provide standardized test scores. Future research should be directed at 
Latent Trait Standardisation of the BCQ, on the basis of a normative population of general 
practice benzodiazepine users. 
Unidimensionality of benzodiazepine craving
The way Tiffany et al.7,8 approached the development of the Questionnaire on Smoking 
Urges (QSU) and the Cocaine Craving Questionnaire (CCQ) appealed to us as a starting 
point for the BCQ, because of the broad scope of their craving definition. The QSU contains 
items from four different conceptual areas relevant to cigarette craving, in order to cover 
current craving theories as widely as possible: ) desire to use, ) anticipation of positive 
outcome, ) anticipation of relief of withdrawal or (withdrawal-associated) negative affect, 
and 4) intention to use. We derived an additional fifth category, ‘lack of control over use’ 
from the CCQ. 
Tiffany et al. propose that craving should be considered as a multidimensional construct. 
Many researchers have shared this view and have supported it with evidence through their 
research (e.g.9-). They found that at a primary level their questionnaires had two to four 
dimensions, representing different aspects of craving report. Nonetheless, these dimensions 
were themselves moderately to strongly intercorrelated, suggesting the presence of one 
higher-order general craving factor.7,8,0,4
For reasons described above, we have chosen a different test methodology for the 
development of the BCQ, by applying the Rasch scaling model on our data. The Rasch 
scaling model held true, leading to a 0-item unidimensional scale, implicating that 
benzodiazepine craving could be defined as a continuum from (almost) none to very high.
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Although unidimensional as a construct, all conceptual areas described above were 
represented in the BCQ. In other words, looking at the item contents, benzodiazepine 
craving still incorporated a variety of features, including not only the desire to use, but 
also aspects of anticipation of positive outcome, anticipation of relief of withdrawal or 
(withdrawal-associated) negative affect, intention to use, and lack of control (see the 
appendix of chapter  for an overview of the Rasch-homogeneous BCQ items; see 
appendix C for an overview of the original 48 items of the BCQ, in Dutch). 
Due to the differences in research methodology and substances under investigation, 
comparability of the abovementioned studies with our study is limited. Further research 
should reveal whether or not the structure of craving is essentially unidimensional for all 
substances of abuse.
Low BCQ sum scores
Average BCQ sum scores were very low. Bendep-SRQ sum scores were also relatively low, 
indicating that the majority of our study population was dependent on their benzodiazepines 
only to a fairly limited extent. We found moderate associations between these two 
variables. Craving and dependence do not seem to be big issues for the majority of our 
study population. 
An additional explanation for the low sum scores was given in chapter , referring to 
long half-lives and slow onset of action of most benzodiazepines compared with other 
substances of abuse in which craving is reported more often and to a higher extent. One 
might also argue that the lack of variance in the sum scores is due to the lack of sensitivity 
of our questionnaire to detect craving in this population. However, this does not seem to 
be the case, since the BCQ was sensitive enough to detect variation in craving over time 
(see chapter 4). Moreover, Rasch scale values indicated sufficient item-spacing in the lower 
regions of the BCQ (confirmed first in case of craving) (see the appendix of chapter ). 
Validity of the BCQ
By lack of a ‘golden standard’ for craving, the validity of the BCQ was assessed by comparing 
it with other (theoretically relevant) measures, in accordance with classical test theory. In 
chapter  construct validity was assessed by associating BCQ sum scores with potentially 
(theoretically) related constructs, resulting in modest construct validity. 
Another approach to assess construct validity is by comparing it with a chosen external 
standard, such as an expert’s clinical judgement. The specific item order, generated if the 
Rasch model holds true, based on increasing Rasch scale values reflecting increasing levels 
of craving, offers a new approach to assess construct validity. Two independent expert 
assessors (physicians) interpreted the specific item order and the contents of the items. This 
made it possible to formulate theoretical rationales that reflected a more thorough 
understanding of the latent trait, i.e. the underlying dimension, supposedly craving. 
Clearly, this interpretation was subjective and the theoretical rationales could be challenged 
by alternative ones. However, the item order determined by the independent assessors 
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can be statistically compared to the item order empirically found in the Rasch analysis 
using Kendall’s tau-c correlation coefficient, with correction for nodes. Substantial 
correlation coefficients were found between the item order given by the two independent 
assessors and the item order found using Rasch analysis (Kendall’s tau-c = .59, p < .000 
and Kendall’s tau-c = .7, p = .005, respectively). The intercorrelation between assessor 
 and assessor  was .5 (p < .00). These findings suggest that the underlying dimension 
(latent trait) is indeed benzodiazepine craving. (personal communication of the author)
Implications of our results in the light of (neuro)biological findings 
In this study (neuro)biological approaches of craving were left aside. From these perspectives, 
theories on the concept and aetiology of craving have been described. 
Many complex neurobiochemical mechanisms have been implicated in the aetiology of 
craving for substances of abuse other than benzodiazepines, involving several neurotransmitter 
systems. Results are mainly based on animal studies.5-7 Benzodiazepines exert their effects 
by binding on the gamma-aminobutyric acid receptor type A (GABAA receptor) enlarging the 
inhibitory effects of GABA, the most frequently used inhibitory neurotransmitter in the 
central nervous system. Discontinuation of benzodiazepines leads to decreased inhibitory 
activity of GABA. One might hypothesise that this, in turn, leads to more arousal and results 
in increased desire (craving) for relief from this arousal. This is in line with one of the three 
pathways of the psychobiological model of alcohol craving proposed by Verheul et al.,7 
named ‘relief craving’ (i.e. a desire for the reduction of tension or arousal, associated with 
the GABAergic/glutaminergic system). We have found that patients who are still using 
benzodiazepines, but who are in the process of discontinuation, experience more severe 
craving than patients who have quit their use. In line with the abovementioned model, it is 
clear that the former subgroup continuously disturbs the GABAergic system with the 
ongoing process of quitting, causing arousal hence leading to ‘relief craving’. However, the 
fact that the patients who experienced craving were more vulnerable in terms of dependence, 
withdrawal symptoms, personality traits, mood aspects, health-related quality of life, and 
psychopathology, suggests the involvement of other neurobiochemical mechanisms in the 
aetiology of craving as well. Further research should lead to a better insight into these 
matters.
EEG, PET and fMRI studies have indicated that craving involves several interacting 
brain regions (for a review, see e.g.5,8,9). Several PET/fMRI studies have found a consistent 
relationship between the degrees of brain activity and self-reported craving in other 
substances of abuse.0, To our knowledge there has not been any research in this area 
directed at benzodiazepines.
Integrating psychological and neurobiochemical approaches offers opportunities to 
further expand our knowledge about the mechanisms underlying craving for benzodiazepines, 
its conceptualisation and its measurement.5
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Implications of our results in the context
of current psychological craving theories
With respect to the items that are confirmed first in case of craving, i.e. in cases of low 
craving severity, the emphasis is on (cognitive aspects of) affect regulation. These items are 
from the item categories anticipation of positive outcome and anticipation of relief of 
withdrawal or (withdrawal-associated) negative affect. In our study population, 
expectations of positive effects of benzodiazepine use constitute the first signs of 
benzodiazepine craving. BCQ items indicative of more severe craving, referring to the 
desire to use benzodiazepines, intention to use and lack of control over use, which are 
present in the higher regions of the Rasch rank order, were hardly confirmed in our study 
population. These items refer to more obvious dependence aspects. Further research into 
other, high-dose and high-dependence, benzodiazepine-using populations should reveal 
whether or not craving in these groups covers the entire spectrum of items. Up till now it 
is unclear whether different groups of users have different craving profiles.,7,
In this thesis we have referred to various cognitive craving theories to explain and 
compare our results with (e.g. the cognitive labelling model in chapter ). Most of the 
cognitive theories are based on the cognitive social learning theory. Although this is 
predominantly a theory of relapse, it has relevance to understanding craving (and its role 
in relapse). It incorporates both positive and negative affect states (whether or not in 
response to cues) and the expectancies of drug effects. In this theory craving is regarded as 
a ‘desire for positive drug effects’, which is in line with the description of benzodiazepine 
craving for our study population. The cognitive social learning theory also invokes 
conditioning theory: ‘craving may be a conditioned response elicited by stimuli associated 
with past gratification’. This theory regards craving and self-efficacy reciprocally related 
(high craving undermines self-efficacy as it challenges the patient’s coping skills). In 
chapter  we have briefly mentioned this possible undermining effect of craving on self-
efficacy and coping, and thereby increasing the likelihood of relapse. In our opinion, 
treatment strategies should take these explicit drug expectancies into account and focus 
on coping without benzodiazepines.
Conditioning theories have taken up a central role in contemporary theories on addiction 
and craving. They have been influential in the development of cue exposure treatments. 
However, the efficacy of these cue exposure therapies as a treatment for addictive disorders 
has been questioned in recent studies (e.g.4,5). A recent review of human-nicotine-
conditioning studies provided evidence for both (emotional) conditioning and expectancies 
in mediating addictive behaviour, among which was subjective craving. 
We believe it is too soon to draw definite conclusions. Results can be looked upon from 
different angles. In general, little research has been directed at testing specific craving 
theories. In addition, none of the theories seem to provide a full explanation of the 
phenomenon of craving.7 As Sayette et al.8 have argued: ‘there is no single craving 
construct; there are as many craving constructs as there are craving theories. Construct 
validity is not derived from a single study; rather it is inferred from the accumulation of 
data through ongoing research’. 




• The benzodiazepine Craving Questionnaire (BCQ) is the first multi-item instrument to 
assess benzodiazepine craving of which the psychometric properties have been 
addressed in detail and have shown to be promising. 
• Benzodiazepine craving, as assessed with the BCQ, can be regarded as a unidimensional 
construct (ranging from almost none to very high). 
• High craving for benzodiazepines is characterised by desire to use, intention to use and 
lack of control. 
• The first signs of craving in benzodiazepine use are represented by expectations of 
positive outcome and expectations of relief from withdrawal or negative affect.
• Patients who report craving for benzodiazepines are significantly less able to quit their 
benzodiazepine use after a minimal intervention (letter from their general practitioner). 
They are a more vulnerable subgroup (with respect to benzodiazepine dependence, 
withdrawal symptoms, personality traits, mood aspects, health-related quality of life, 
and psychopathology) than patients who do not report craving. 
• BCQ sum scores may give direction to the advisable treatment intensity, in terms of 
type of intervention by the general practitioner, when a patient is trying to abstain 
from benzodiazepines.
• In long-term benzodiazepine users who receive additional treatment to discontinue 
benzodiazepine use successfully, i.e. a supervised tapering off protocol after a failed 
attempt to quit on their own, benzodiazepine craving predicts relapse during a 
5-month follow-up period independent of other predictors.
• The BCQ is able to monitor and quantify self-reported benzodiazepine craving 
longitudinally.
• After taking part in a discontinuation trial, the severity of craving decreases over time 
for both patients who are able to quit their benzodiazepine use and patients who 
continue taking benzodiazepines.
• In our study the majority of long-term benzodiazepine users in general practice hardly 
experiences any craving at all, either while still using or after having quit. Nonetheless, 
about % of our patients indicated to experience benzodiazepine craving to some 
extent. In addition, the data suggested that the most severely dependent patients (with 
possibly the highest degree of craving) did not participate in the study. 
• Benzodiazepine craving in our general practice population is associated with negative 
affect. This underlines the importance of achieving a more precise understanding of 
negative affect (both as state and trait manifestations) as a possible cue for 
benzodiazepine craving. If certain mood states are cues for benzodiazepine craving 
they demand treatment attention. 
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RECOMMENDATIONS FOR FUTURE STUDIES
The BCQ can be improved further. Firstly, reliability and validity could gain from adding 
new items to the BCQ. These should be formulated in line with the theoretical rationale 
(i.e. craving) of the BCQ. Formulating appropriate new items would contribute to the 
improvement of ‘equal item spacing’, especially in the higher regions of the BCQ (confirmed 
only in case of more severe craving). Removing items without item spacing will lead to a 
more efficient questionnaire. 
Secondly, it is important to repeat our research in other populations, e.g. psychiatric 
inpatients, inpatients at drug centres (multi-drug users) and general hospital inpatients. 
Theoretically, the Rasch scaling model has been shown to be population-independent. It 
can therefore be expected to hold true in other benzodiazepine using populations as well. 
Repeating our study will contribute, however, to obtaining a better understanding of 
benzodiazepine craving. 
Thirdly, future research should also be directed at Latent Trait Standardisation of the 
BCQ, on the basis of a normative population of general practice benzodiazepine users. 
Latent Trait Standardisation requires the Rasch scaling model with the additional 
assumption of a normally distributed latent trait. It would make raw BCQ scores clinically 
interpretable in relation to the normative general practice sample of benzodiazepine users. 
Clearly, as stated in chapter  good psychometric characteristics may be considered 
only a basic requirement for the usefulness of an instrument. Further research is needed to 
reveal the clinical utility of the BCQ in terms of its contribution to the effectiveness of 
treatment interventions. Follow-up data gathered at the start and at different follow-up 
stages of benzodiazepine reduction trials in other populations may provide more insight in 
the role of craving in successful abstinence and relapse.
CLINICAL IMPLICATIONS
It has become clear from this study that, although not to a very large extent, craving for 
benzodiazepines can be an issue for some long-term general practice benzodiazepine users. 
Physicians should be aware of this.
At this stage of the development of the BCQ, we can only speculate about its future 
clinical implications. When the results of our study hold up in future research, a completed 
BCQ may give physicians information on how to proceed when a patient expresses the 
wish to discontinue benzodiazepine use. It may give direction to the appropriate treatment 
intensity (supervised tapering off or not). To some extent, it can inform physicians about 
the patient’s vulnerability in terms of e.g. personality, especially negative affect. And 
finally, when a patient indicates to experience craving on the BCQ, physicians should be 
aware of the chance of relapse even after supervised tapering off. Furthermore, on the 
basis of the contents of the confirmed items, the physician could engage in a dialogue with 
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the patient about the expectations of the effects of benzodiazepines, and focus on how to 
cope without benzodiazepines. This could help the patient-physician working alliance and, 
in turn, the patient’s motivation and self-efficacy to quit benzodiazepine use and cope 
with craving.
Finally, in clinical practice the utility of an instrument also depends on the amount of 
time that is required to administer the instrument. The amount of time it takes to complete 
the BCQ is limited and it does not require special training.
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Benzodiazepine Craving Questionnaire (BCQ)
A.J.J. Mol, M.H.M. Breteler, F.G. Zitman
Tijdstip invullen BCQ: |___|___|:|___|___| uur
Patiënt gebruikt BZ als slaapmiddel/kalmeringsmiddel/beide (omcirkel wat van toepassing is)
Datum laatste BZ gebruik: |___|___|-|___|___|-20|___|___|
Tijdstip laatste BZ gebruik: |___|___|:|___|___| uur
Instructie
Alle beweringen in deze vragenlijst gaan alléén over de slaap- en kalmeringsmiddelen (behorend tot de 
benzodiazepinen, afgekort als BZ) die u daarnet heeft opgegeven. Als het in de vragen gaat over “de BZ”, “een 
BZ” of “BZ” dan worden alléén deze slaap- en kalmeringsmiddelen bedoeld.
Voorbeeld
De vraag “Als ik nu een BZ zou nemen dan zou ik me minder geremd voelen.”
Als u bijvoorbeeld valium (diazepam) gebruikt(e) leest u: “Als ik nu valium zou nemen dan zou ik me minder 
geremd voelen.”
Wilt u aangeven in welke mate u het eens of oneens bent met de volgende beweringen door een kruisje te 
zetten op iedere lijn tussen ERG MEE ONEENS en ERG MEE EENS. 
Zo: |___|
Hoe dichter u uw kruisje zet bij “erg mee oneens”, hoe meer u het met de bewering oneens bent. Hoe dichter u 
uw kruisje zet bij “erg mee eens”, hoe meer u het met de bewering eens bent.
Vult u alstublieft iedere vraag in!
We willen graag weten wat u op dit moment, terwijl u de vragenlijst invult, denkt of voelt. 
Introduction and thesis outline
07
1 Het innemen van een BZ zou me nu gelukkiger maken.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
2 Ik bedenk manieren om aan BZ te komen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
3 Als ik nu een BZ zou hebben ingenomen zou ik helderder kunnen denken.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
4 Als ik een BZ zou innemen zou ik me op dit moment erg goed voelen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
5 Op dit moment mis ik de BZ.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
6 Ik zou op dit moment bijna alles doen voor een BZ.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
7 Ik zou me erg alert voelen als ik nu een BZ zou innemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
8 Ik zou nu minder prikkelbaar zijn als ik een BZ zou kunnen innemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
9 Ik zou de hoeveelheid BZ die ik gebruik nauwelijks in de hand kunnen houden als ik er enkele bij me had.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
10 Op dit moment snak ik naar een BZ.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
11 Ik moet nu een BZ innemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
12 Ik zou mezelf nauwelijks kunnen tegenhouden BZ te gebruiken als ik er nu hier wat had.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
13 Door het innemen van een BZ zou ik me nu minder vermoeid voelen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
14 Niets zou beter zijn dan op dit moment een BZ innemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
15 Het innemen van een BZ zou me minder neerslachtig maken.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
16 Op dit moment heb ik dringend behoefte aan een BZ.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
17 Als ik een BZ aangeboden zou krijgen, zou ik hem onmiddellijk innemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
18 Nu een BZ innemen zou ervoor zorgen dat de dingen volmaakt lijken.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
19 Als ik op dit moment een BZ zou hebben ingenomen, zou ik me minder vervelen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
20 Het zou moeilijk zijn om nu direct BZ af te slaan.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
vervolg op de volgende pagina
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21 Mijn verlangen om een BZ te nemen lijkt overweldigend.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
22 Als er een BZ vlak voor me zou liggen zou het moeilijk zijn hem te laten liggen. 
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
23 Op dit moment verlang ik naar een BZ.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
24 Ik wil nu een BZ innemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
25 Ik zou de boel op dit moment beter onder controle hebben als ik een BZ kon innemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
26 Ik zou op dit moment van een BZ genieten.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
27 Als ik nu een klein beetje BZ zou gebruiken, zou ik mezelf er nauwelijks van kunnen
 weerhouden om meer in te nemen. 
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS 
28 Als ik nu een BZ zou nemen dan zou ik me minder geremd voelen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
29 Het enige dat ik op dit moment wil is een BZ.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
30 Ik ga zo snel mogelijk een BZ nemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
31 Ik zou me energiek voelen als ik BZ zou innemen.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
32 Ik zal een BZ nemen zodra ik de kans krijg.
 ERG MEE ONEENS |___|___|___|___|___|___|___| ERG MEE EENS
- Bedankt voor uw medewerking -
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APPENDIX B
Benzodiazepine Desire Scale (BDS)
A.J.J. Mol, M.H.M. Breteler, F.G. Zitman
Instructie
Beantwoord de onderstaande beweringen op een schaal van 1 tot 10 door een kruisje te zetten in het hokje dat 
het meest voor u van toepassing is.
A Welk deel van de tijd ervoer u een verlangen naar benzodiazepinen in de afgelopen week? 
 (d.w.z. uw verlangen naar een slaap- of kalmeringsmiddel, terwijl u er geen had ingenomen.)
 nooit |___|___|___|___|___|___|___|___|___|___| constant
B Hoe hevig was uw verlangen naar benzodiazepinen in de afgelopen week over het algemeen? 
 (d.w.z. uw verlangen naar een slaap- of kalmeringsmiddel, terwijl u er geen had ingenomen.)
 weinig of geen verlangen |___|___|___|___|___|___|___|___|___|___| erg sterk verlangen
C Probeert u zich het moment in de afgelopen week te herinneren waarop uw verlangen naar benzodiazepinen 
het hevigst was. (d.w.z. uw verlangen naar een slaap- of kalmeringsmiddel, terwijl u er geen had 
ingenomen.) Hoe sterk was het verlangen op dat moment?
 weinig of geen verlangen |___|___|___|___|___|___|___|___|___|___| onweerstaanbaar verlangen




Original 48 items of the BCQ (in Dutch) 
Oorspronkelijke 48 BCQ items, geordend naar itemcategorie
i ii iii
DESIRE TO USE
Op dit moment mis ik de BZ. x 1 c
Op dit moment snak ik naar een BZ. x 1
Ik moet nu een BZ innemen. x 1 d
Op dit moment heb ik dringend behoefte aan een BZ. x 1 d
Mijn verlangen om een BZ te nemen lijkt overweldigend. 1
Op dit moment verlang ik naar een BZ. 1 c
Ik wil nu een BZ innemen. x 1 c
Het enige dat ik op dit moment wil is een BZ. x 1
ANTICIPATION OF POSITIVE OUTCOME
Het innemen van een BZ zou me nu gelukkiger maken. 1
Als ik nu een BZ zou innemen zou ik nauwelijks beter slapen. a, e
Als ik een BZ zou innemen zou ik me op dit moment erg goed voelen. x 1
Als ik nu een BZ zou innemen, dan zou ik de situatie nauwelijks beter in de hand hebben. a, e
Als ik nu een BZ zou innemen zou ik me nauwelijks ontspannener voelen. a, e
Ik zou me erg alert voelen als ik nu een BZ zou innemen. 2
Een BZ zou nu weinig voldoening geven. 2 a
Niets zou beter zijn dan op dit moment een BZ innemen. x 1
Het innemen van een BZ zou onaangenaam zijn. 1 a
Nu een BZ innemen zou ervoor zorgen dat de dingen volmaakt lijken. 2
Een BZ zou me op dit moment slecht bevallen. 1 a
Ik zou op dit moment van een BZ genieten. x 1 c
Als ik nu een BZ zou nemen dan zou ik me minder geremd voelen. x e
Ik zou me energiek voelen als ik BZ zou innemen. x 2
ANTICIPATION OF WITHDRAWAL OR NEGATIVE AFFECT
Ik zou me lichamelijk nauwelijks beter voelen als ik een BZ zou hebben ingenomen. 1 a, b
Het innemen van een BZ zou me nu nauwelijks helpen om rustiger te worden. 1 a, b
Als ik nu een BZ zou hebben ingenomen zou ik helderder kunnen denken. 1
Ik zou nu minder prikkelbaar zijn als ik een BZ zou kunnen innemen. 1
Door het innemen van een BZ zou ik me nu minder vermoeid voelen. x 1
Het innemen van een BZ zou me minder neerslachtig maken. x 1
Als ik op dit moment een BZ zou hebben ingenomen, zou ik me minder vervelen. 1
Ik zou de boel op dit moment beter onder controle hebben als ik een BZ kon innemen. x 1
Als ik een BZ zou gebruiken zou mijn ergernis nauwelijks verminderen. a, e




Ik bedenk manieren om aan BZ te komen. 2
Vanaf nu zou ik het heel lang kunnen uithouden zonder BZ. 1 a
Op dit moment heb ik geen plannen om een BZ in te nemen. 1 a
Ik zou op dit moment bijna alles doen voor een BZ. x 1
Als ik de kans had om een BZ in te nemen, dan zou ik er waarschijnlijk van afblijven. 2 a
Als ik een BZ aangeboden zou krijgen, zou ik hem onmiddellijk innemen. x 1
Al had ik een tablet in de hand die net uit de strip was gedrukt, dan zou ik hem waarschijnlijk laten liggen. 1 a
Ik ga zo snel mogelijk een BZ nemen. x 1
Ik zal een BZ nemen zodra ik de kans krijg. x 1
LACK OF CONTROL OVER USE
Ik zou de hoeveelheid BZ die ik gebruik nauwelijks in de hand kunnen houden als ik er enkele bij me had. x 2 b
Ik zou mezelf nauwelijks kunnen tegenhouden BZ te gebruiken als ik er nu hier wat had x 2 b
Ik zou makkelijk in de hand kunnen houden hoeveel BZ ik op dit moment zou gebruiken. 2 a
Ik denk dat ik de verleiding om een BZ in te nemen nu kan weerstaan. 2 a
Het zou moeilijk zijn om nu direct BZ af te slaan. 2
Als er een BZ vlak voor me zou liggen zou het moeilijk zijn hem te laten liggen. 2
Het zou gemakkelijk zijn om de kans om BZ te gebruiken te laten schieten. 2 a
Als ik nu een klein beetje BZ zou gebruiken, zou ik mezelf er nauwelijks van kunnen weerhouden om
meer in te nemen.
2 b
i) De 20 items die de Rasch homogene schaal vormen
 ii) Lijst van herkomst. 1=Questionnaire on Smoking Urges; 2=Cocaine Craving Questionnaire
iii)  a. Reverse-keyed items die, naar aanleiding van pilotresultaten, uit de lijst zijn verwijderd en niet meededen in de analyses.
 b. Oorspronkelijk item was negatief verwoord (in Engels: ‘not’)
 c. Oorspronkelijk item was reverse-keyed
 d. Oorspronkelijk item herschreven voor een beter begrip in het Nederlands
 e. Item is niet aanwezig in QSU of CCQ
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The development of the Benzodiazepine Craving Questionnaire 
This thesis describes the development and initial validation of the Benzodiazepine Craving 
Questionnaire, a Rasch-homogeneous self-report questionnaire to assess craving for 
benzodiazepines. This questionnaire was developed as part of the Benzoredux project, 
which was designed to evaluate a stepped-care approach to reduce long-term benzodiazepine 
use in general practice.
In chapter 1 some aspects of (long-term) benzodiazepine use are discussed, such as its 
definition and prevalence, and drawbacks of this use, e.g. dependence. Subsequently, we 
address the role of craving in dependence on addictive substances, and discuss some 
models of craving and recent developments in craving research. We find that benzodiazepine 
craving research is scarce and that a good benzodiazepine craving questionnaire is lacking. 
These observations are the starting point of the development of the Benzodiazepine 
Craving Questionnaire and of this thesis.
In chapter 2 we describe the development and initial validation of a newly constructed 
self-report questionnaire assessing craving for benzodiazepines, the Benzodiazepine 
Craving Questionnaire (BCQ). The BCQ was administered to a sample of  long-term and 
80 former long-term general practice benzodiazepine users participating in the Benzoredux 
project. The BCQ met the requirements for Rasch homogeneity, i.e. self-reported 
benzodiazepine craving as assessed by this questionnaire can be regarded as a 
unidimensional construct. Reliability, as indicated by the subject and item discriminability, 
was good. Construct validity was modest: correlations between BCQ sum scores and other 
variables (dependence, personality, and psychopathology) were low. Discriminative validity 
was satisfactory. The first signs of craving were represented by the acknowledgement of 
expectations of positive outcome and of relief of withdrawal or negative affect, whereas 
desire, lack of control over use and direct intention to use were only found in cases of high 
craving. The BCQ was found to be a reliable and psychometrically sound self-report 
instrument to assess benzodiazepine craving in a general practice population of (former) 
long-term benzodiazepine users.
Chapter 3 aims to describe characteristics of patients reporting craving for benzodiazepines 
and to search for associations between benzodiazepine craving and other clinical variables 
in a population of general practice patients who had made an attempt to discontinue their 
long-term benzodiazepine use. Patients reporting craving for benzodiazepines on the BCQ 
differed significantly from patients not reporting craving on aspects of benzodiazepine 
dependence severity, psychological well-being, aspects of health-related quality of life, 
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aspects of a negative mood state (depression and anger), and certain personality traits 
(somatisation and negativism). Furthermore, in a multivariate analysis, controlling for 
current use status, depression and somatisation were positively associated with 
benzodiazepine craving. However, only the contribution of depression to craving was 
statistically significant for the total group of (former) benzodiazepine users (p = .00). 
These results call for further research with respect to the relationship between personality 
and benzodiazepine craving. 
Since craving for different substances of abuse has been described to fluctuate over time, 
it is important that craving questionnaires are sensitive to changes over time. Therefore, in 
chapter 4 we have aimed to assess benzodiazepine craving longitudinally and have 
described its course by means of the BCQ. A subset of 7 (former) long-term benzodiazepine 
users received four repeated measurements of the BCQ, taken over a -month follow-up 
period. Results indicated that benzodiazepine craving severity decreased over time. Patients 
still using benzodiazepines experienced significantly more severe craving than patients 
who had quit their use after either a minimal intervention (letter from their general 
practitioner with the advice to quit their use) or after a subsequent randomised controlled 
trial (tapering off programme with or without additional group cognitive-behavioural 
therapy). The method of discontinuation did not influence the experienced craving severity 
over time. However, patients who had received the additional tapering off programme, on 
average, reported significantly more severe craving than patients who had only received a 
letter from their general practitioner as an incentive to quit. It was concluded that, although 
benzodiazepine craving was prevalent among (former) long-term benzodiazepine users in 
our study population during and after discontinuation, it decreased over time to minimal 
proportions. Nevertheless, the BCQ proved to be an instrument capable of monitoring and 
quantifying craving for benzodiazepines longitudinally and it was sensitive enough to 
discriminate between different subgroups. The BCQ sum scores may give direction to the 
advisable treatment intensity, in terms of type of interference by the general practitioner, 
when a patient is trying to abstain from benzodiazepines.
Chapter 5 addresses the scope of the craving definition (broad versus narrow). We 
compared a broad conceptualisation of benzodiazepine craving, as represented by the 
BCQ, with a narrow one, as represented by the sum score of three one-item Likert-type 
scales assessing the frequency, global intensity and peak intensity of the desire for 
benzodiazepines when not using (the Benzodiazepine Desire Scale, BDS). In a factor 
analysis the BCQ loaded on a factor representing negative affect, while the BDS loaded on 
a dependence factor. Apparently, low craving, as measured with the BCQ, is associated 
with negative affect and reflects the anticipation of positive outcome of benzodiazepine 
use and of relief from negative affect or withdrawal. The low BCQ sum scores in our study 
population and the selected time frame of the craving measurement (current experience 
versus over the past week) were the most likely explanations for our findings. Both 
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conceptualisations of benzodiazepine craving contribute to our understanding of the 
potential significance and meaning of craving in benzodiazepine use.
Chapter 6 presents a Cox-regression analysis used to identify independent predictors of 
relapse after benzodiazepine discontinuation, with time to relapse as the dependent 
variable. Potential predictors included benzodiazepine (usage) characteristics, 
psychopathological symptoms, personality traits and characteristics of benzodiazepine 
dependence, including craving as measured with the BCQ. The BCQ sum score had no 
predictive value with respect to relapse after a minimal intervention (letter from the general 
practitioner). However, independent predictors of relapse during a 5-month follow-up 
period after a tapering off programme included higher craving sum scores on the BCQ, 
higher age, public health insurance, and higher ‘lack of compliance’ with the therapeutic 
benzodiazepine regimen. These results should guide relapse prevention programmes by 
including treatment elements with a focus on (coping with) craving experiences.
Chapter 7 mainly considers points of discussion that have not been addressed in the 
previous chapters. Furthermore, the major conclusions are presented along with 
recommendations for further research and some clinical implications.
First of all, we examine the generalisability of our results further and conclude that 
generalisability was probably reduced due to the large amount of patients who refused to 
take part in the Benzoredux study. Mainly low-dose benzodiazepine users took part in the 
study. Benzodiazepine dependence might have played a role here. Our findings probably 
represent daily clinical practice, as particularly those patients will take part in a 
discontinuation trial who are prepared to try to discontinue their benzodiazepine taking. 
Therefore the present study should be repeated in a less selective sample. 
With regard to the development of the BCQ, the pros and cons of the use of the Rasch 
scaling model as compared with ‘classical test theory’ are addressed. The ‘item response 
theory’ or ‘latent trait theory’ on which the Rasch scaling model is based, justifies the use 
of the BCQ sum score as a measure for the underlying unidimensional construct of craving. 
The BCQ sum scores were low on average, which indicates that craving did not seem to be 
a big issue in our study population.
Comparing our study results with (neuro)biological findings from craving research into 
other substances of abuse, we have found some similarities with ‘relief craving’, as described 
in the ‘three-pathway psychobiological model of craving for alcohol’. However, 
benzodiazepine craving research in this field of expertise is lacking.
In our study population, expectations of positive effects of benzodiazepine use 
constitute the first signs of benzodiazepine craving. This makes our study results 
interpretable from the perspective of different cognitive theories on craving, e.g. the 
cognitive social learning theory. Treatment strategies should take these explicit drug 
expectancies into account.




use benzodiazepines, the intention to use, and lack of control over use, were hardly 
confirmed in our study population. Further research in other, high-dose and high-
dependence benzodiazepine-using populations should reveal whether craving in these 
groups covers the entire spectrum of BCQ items. Up till now it is unclear whether different 
groups of users have different craving profiles. 
In addition to repeating the present study in different populations, the usefulness of the 
BCQ can be further improved by means of Latent Trait Standardisation on the basis of a 
normative population of general practice benzodiazepine users. It would make raw BCQ 
scores clinically interpretable in relation to the normative population. This would increase 
the usefulness of the BCQ in benzodiazepine reduction programmes in general practice.
Reference
 Verheul R, Van den Brink W, Geerlings P. A three-pathway psychobiological model of 
craving for alcohol. Alcohol & Alcoholism 999;4():97-
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Samenvatting
CRAVING NAAR BENZODIAZEPINEN 
De ontwikkeling van de Benzodiazepine Craving Questionnaire
Dit proefschrift beschrijft de ontwikkeling en een eerste psychometrische evaluatie van de 
Benzodiazepine Craving Questionnaire, een Rasch-homogene zelf-rapportage vragenlijst 
om de mate van craving (hunkering) naar benzodiazepinen in kaart te brengen. Deze 
vragenlijst werd ontwikkeld in het kader van het Benzoredux-project. Het Benzoredux-
project was ontworpen om een getrapte benadering, gericht op het terugdringen van 
langdurig benzodiazepinegebruik in de huisartspraktijk, te evalueren.
In hoofdstuk 1 worden enkele aspecten van (langdurig) benzodiazepinegebruik belicht, 
zoals de definitie, de prevalentie en de nadelen van dit gebruik, waaronder afhankelijkheid. 
Vervolgens wordt ingegaan op de rol van craving bij afhankelijkheid van verslavende 
middelen. Ook worden enkele cravingmodellen en recente ontwikkelingen op het gebied 
van cravingonderzoek besproken. Er wordt vastgesteld dat onderzoek naar craving bij 
benzodiazepinegebruik schaars is en dat een goede vragenlijst om benzodiazepinecraving 
in kaart te brengen ontbreekt. Deze constateringen vormen het vertrekpunt van de 
ontwikkeling van de Benzodiazepine Craving Questionnaire en van dit proefschrift.
In hoofdstuk 2 wordt de ontwikkeling en eerste validering van een nieuwe zelf-rappor-
tage vragenlijst beschreven die craving naar benzodiazepinen meet: de Benzodiazepine 
Craving Questionnaire (BCQ). De BCQ is afgenomen bij een groep van  langdurige 
gebruikers en 80 voormalige langdurige gebruikers, allen huisartspatiënten die meededen 
aan het Benzoredux-project. De BCQ voldeed aan de vereisten voor Rasch-homogeniteit. 
Dit betekent dat zelf-gerapporteerde benzodiazepinecraving, zoals gemeten met de BCQ, 
beschouwd moet worden als een unidimensioneel construct. De betrouwbaarheid van de 
BCQ, zoals bepaald werd door middel van de subject-discriminabiliteit en item-
discriminabiliteit, kon als goed worden beschouwd. De constructvaliditeit was matig: de 
samenhang tussen de somscores van de BCQ en andere variabelen (afhankelijkheid, 
persoonlijkheid, psychopathologie) was laag. De discriminatieve validiteit was toereikend. 
Verwachtingen omtrent een positief effect van het gebruik van de benzodiazepine en 
verwachtingen omtrent de verlichting van ontwenningsverschijnselen of een negatief 
affect, konden worden beschouwd als de eerste tekenen van craving. Alleen in geval van 
een hoge mate van craving was er daarnaast ook sprake van verlangen, controleverlies en 
de directe intentie om te gebruiken. De BCQ bleek een betrouwbaar en psychometrisch 
deugdelijk zelf-rapportage instrument te zijn om benzodiazepinecraving te meten in een 
huisartspatiëntenpopulatie van (voormalige) langdurige benzodiazepinegebruikers.
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Hoofdstuk 3 beschrijft de kenmerken van patienten die craving naar benzodiazepinen 
rapporteren. Daarnaast werd gezocht naar associaties tussen benzodiazepinecraving en 
andere klinische variabelen. Dit alles in een huisartspatiëntengroep die een poging deed 
om het benzodiazepinegebruik te staken. Patiënten die craving rapporteerden op de BCQ 
verschilden significant van patiënten die geen craving rapporteerden wat betreft de mate 
van afhankelijkheid, psychologisch welbevinden, aspecten van gezondheidsgerelateerde 
kwaliteit van leven, aspecten van een negatieve gemoedstoestand (depressie en boosheid) 
en bepaalde persoonlijkheidseigenschappen (somatisatie en negativisme). In een 
multivariate analyse, die controleerde voor de huidige gebruiksstatus, bleek, dat depressie 
en somatisatie positief samenhingen met craving. Echter, alleen de bijdrage van de 
variabele depressie aan craving was significant voor de gehele groep van (voormalige) 
langdurige gebruikers (p = .00). Deze resultaten in ogenschouw nemende, zou in 
toekomstig onderzoek de relatie tussen persoonlijkheid en benzodiazepinecraving verder 
onder de loep moeten worden genomen.
Uit de literatuur over craving bij andere verslavende stoffen is gebleken dat de mate van 
craving kan fluctueren over de tijd. Het is daarom belangrijk dat een cravingvragenlijst 
sensitief genoeg is om veranderingen in het verloop van craving over de tijd in kaart te 
brengen. Derhalve wilden we in hoofdstuk 4 met behulp van de BCQ benzodiazepinecraving 
over een langere tijd beoordelen en het verloop ervan beschrijven. Een subgroep van 7 
(voormalige) langdurige gebruikers kreeg viermaal de BCQ voorgelegd over een follow-
upperiode van  maanden. De ervaren craving bleek af te nemen over de tijd. Patiënten die 
benzodiazepinen bleven gebruiken ervoeren significant meer craving dan patiënten die hun 
gebruik hadden gestaakt na een minimale interventie (brief met stopadvies van hun 
huisarts) of na een aansluitende ‘randomised controlled trial’ (afbouwprogramma met of 
zonder aanvullende cognitieve gedragstherapie in een groep). De methode van stoppen had 
geen invloed op de mate van craving die de patiënten over de tijd ervoeren. Echter, patiënten 
die meededen aan het aansluitende afbouwprogramma rapporteerden gemiddeld genomen 
meer craving dan patiënten die alleen de brief van hun huisarts hadden gekregen als een 
aanmoediging om te stoppen. Concluderend kan men stellen dat benzodiazepinecraving, 
hoewel het zowel tijdens als na het afbouwproces voorkomt onder de (voormalige) 
langdurige benzodiazepinegebruikers, afneemt over de tijd tot minimale omvang. Desalniet-
temin bleek de BCQ in staat om benzodiazepinecraving longitudinaal te monitoren en te 
kwantificeren. Bovendien was het instrument sensitief genoeg om een onderscheid te 
kunnen maken tussen verschillende subgroepen in het verloop van craving. De somscores 
van de BCQ kunnen richtinggevend zijn voor de aan te raden intensiteit van de behandeling, 
in termen van de mate van bemoeienis door de huisarts, wanneer een patiënt het 
benzodiazepinegebruik wil staken. 
Hoofdstuk 5 gaat in op de ‘reikwijdte’ van de definitie van craving (breed versus smal). We 
vergeleken een brede en een smalle conceptualisatie van benzodiazepinecraving met 
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elkaar. De brede conceptualisatie werd gerepresenteerd door de BCQ en de smalle door de 
Benzodiazepine Desire Scale (BDS). De BDS bestaat uit drie één-item Likert-type schaaltjes, 
waarop de patiënt de frequentie, de globale intensiteit en de piekintensiteit van het 
verlangen naar benzodiazepinen moet aangeven, wanneer de patiënt op dat moment niet 
gebruikt. In een factoranalyse bleek de BCQ op een factor te laden die te labelen was als 
een ‘negative affect’-factor, terwijl de BDS laadde op een ‘afhankelijkheid’-factor. 
Klaarblijkelijk hangt een lage mate van craving, zoals gemeten met de BCQ, samen met 
negatief affect en weerspiegelt het de verwachting van een positief effect van het gebruik 
van benzodiazepinen en de verwachting van verlichting van negatief affect of 
ontwenningsverschijnselen. De lage somscores op de BCQ in onze studiepopulatie en de 
geselecteerde tijdspanne van het meten van craving (craving op dit moment versus 
gedurende de afgelopen week) waren de meest voor de hand liggende verklaringen voor 
deze bevindingen. Beide conceptualisaties van benzodiazepinecraving dragen bij aan het 
begrip van de potentiële betekenis van craving bij benzodiazepinegebruik.
Hoofdstuk 6 presenteert de uitkomsten van een Cox-regressie analyse ter identificatie van 
onafhankelijke voorspellers van terugval na het staken van benzodiazepinegebruik, met 
tijd tot terugval als afhankelijke variabele. Als potentiële voorspellers werden benzo- 
diazepine(gebruiks)karakteristieken, psychopathology, persoonlijkheidskenmerken en 
karakteristieken van benzodiazepine-afhankelijkheid, waaronder craving zoals gemeten 
met de BCQ, meegenomen. De BCQ somscore had geen voorspellende waarde bij terugval 
na een minimale interventie (brief met stopadvies van de huisarts). Echter, onafhankelijke 
voorspellers van terugval gedurende een follow-upperiode van 5 maanden na een 
afbouwprogramma waren: hogere craving somscores op de BCQ, een hogere leeftijd, het 
hebben van een ziekenfondsverzekering, en een hogere score op de schaal ‘gebrek aan 
therapietrouw’ van de Bendep-SRQ. Deze resultaten zouden richting moeten geven aan 
relapsepreventieprogramma’s door het includeren van behandelonderdelen die zich richten 
op het ervaren van en het omgaan met craving.
Hoofdstuk 7 geeft een algemene beschouwing die met name is gericht op punten van 
discussie die niet in de voorgaande hoofdstukken aan de orde zijn gekomen. Daarnaast 
wordt een opsomming gegeven van de belangrijkste conclusies uit dit onderzoek, worden 
aanbevelingen voor verder onderzoek gedaan en worden enkele klinische implicaties 
besproken. 
Allereerst wordt ingegaan op de generaliseerbaarheid van de onderzoeksresultaten, 
waarbij geconcludeerd wordt dat deze mogelijk beperkt is door het grote aantal patiënten 
dat weigerde deel te nemen aan de Benzoredux-studie. Het waren vooral gebruikers van 
lage doseringen die deelnamen. Mogelijk speelde afhankelijkheid hierbij een rol. Hoewel 
de resultaten waarschijnlijk representatief zijn voor de dagelijkse klinische praktijk, omdat 
juist die patiënten deelnemen aan een afbouwtraject die bereid zijn om te stoppen, zou de 
studie moeten worden herhaald in een minder selectieve groep. 
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Met betrekking tot de ontwikkeling van de BCQ wordt ingegaan op de voordelen en 
nadelen van het gebruik van het Rasch-schaalmodel ten opzichte van de ‘klassieke 
testtheorie’. De ‘itemresponstheorie’ ofwel ‘latente-trektheorie’ waarop het Rasch-schaal-
model is gebaseerd, rechtvaardigt het gebruik van de BCQ somscore als maat voor het 
onderliggende unidimensionele construct craving. De BCQ somscores waren over het 
algemeen laag, wat erop lijkt te duiden dat craving in onze studiepopulatie geen belangrijke 
rol speelt. 
Wanneer we de resultaten van het onderzoek vergelijken met (neuro)biologische 
bevindingen op het gebied van craving bij andere middelen, vinden we overeenkomsten 
met ‘relief craving’ zoals wordt beschreven in het ‘three-pathway psychobiological model 
of craving for alcohol’. Onderzoek naar benzodiazepinecraving op dit gebied ontbreekt 
echter.
In onze studiepopulatie vormen verwachtingen van positieve effecten van benzodiaze-
pinegebruik de eerste tekenen van craving naar benzodiazepinen. Onze studieresultaten 
zijn daarmee te interpreteren vanuit verschillende bestaande cognitieve cravingtheorieën, 
waaronder de cognitieve sociale leertheorie. Tijdens een (afbouw)behandeling zouden de 
expliciete verwachtingen van een patiënt over de effecten van benzodiazepinen aandacht 
moeten krijgen.
In onze studiepopulatie worden items van de BCQ die indicatief zijn voor een hoge mate 
van craving nauwelijks bevestigend beantwoord. Het zijn de items die verwijzen naar een 
verlangen om te gebruiken, de intentie om te gebruiken en het gebrek aan controle over het 
benzodiazepinegebruik. Onderzoek in patiëntenpopulaties die hogere doseringen gebruiken 
en/of een hogere mate van benzodiazepine-afhankelijkheid aangeven, zal moeten uitwijzen 
of craving in deze groepen het gehele spectrum van BCQ items beslaat. Momenteel is nog 
onduidelijk of verschillende gebruikersgroepen verschillende cravingprofielen hebben. 
Behalve door het herhalen van onderhavig onderzoek in andere populaties, kan de 
bruikbaarheid van de BCQ verder worden verbeterd door ‘Latent Trait Standardisation’ op 
basis van een normatieve populatie van benzodiazepinegebruikers uit de huisartspraktijk. 
Door de ruwe BCQ somscores te vergelijken met deze normatieve groep worden ze klinisch 
interpretabel. Dit zal de toepasbaarheid van de BCQ bij benzodiazepine-afbouwprogramma’s 
in de huisartspraktijk vergroten.
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Toen ik in 997 voor het eerst in aanraking kwam met benzodiazepinen, had ik nooit 
gedacht dat ik er tien jaar later pas mee zou kunnen stoppen. 
Bovenstaande zou gezegd kunnen zijn door een benzodiazepinegebruiker, maar het is 
van toepassing op mijzelf. De ‘verslavende’ werking van benzo’s was al die jaren evident: 
verschillende stoppogingen, terugval, veel tijd ermee kwijt zijn - soms ten koste van andere 
plezierige activiteiten, en niet te vergeten... craving. 
Stoppen met benzo’s bleek in mijn geval moeilijker dan gedacht. Gelukkig maar, want 
stug ermee doorgaan heeft het proefschrift opgeleverd dat voor u ligt. Het promotietraject 
was in vele opzichten een leerproces. ‘Aún aprendo’ (‘ik leer nog steeds’) was de titel van het 
schilderij van Francisco de Goya dat in 997 de voorkant van mijn scriptie over chronisch 
benzodiazepinegebruik door ouderen sierde. Het is gelukkig nog steeds van toepassing!
Via deze weg wil ik graag iedereen bedanken die op één of andere manier betrokken 
was bij de totstandkoming van mijn proefschrift. Een aantal mensen wil ik in het bijzonder 
noemen.
Allereerst wil ik de hoofdonderzoekers van het Benzoredux-project bedanken. Eloy van de 
Lisdonk en Ton van Balkom waren zeer nauw betrokken bij de opzet en uitvoering van dit 
project. Ik heb hun kritische en constructieve commentaar op alle versies van mijn artikelen 
bijzonder op prijs gesteld. 
Richard en Wim, mijn mede-onderzoekers op het Benzoredux-project en kamergenoten, 
al vanaf het allereerste begin stond het voor mij vast dat, als ik ooit zou gaan promoveren 
op dit onderzoek, ik jullie als mijn paranimfen zou vragen. Ik ben blij dat jullie ‘ja’ hebben 
gezegd! Met veel plezier denk ik terug aan de jaren dat we met z’n drieën op de Benzoredux-
kamer aan het werk waren. Als ik Richard bedank, moet ik ook Marco bedanken, voor z’n 
gastvrijheid al die keren dat ik in de avonduren of in het weekend ‘even’ met Richard aan 
een artikeltje kwam werken.
Jan Mulder, bedankt voor de statistische ondersteuning en de tijd die je daarvoor 
vrijmaakte, terwijl je die eigenlijk niet had. Cees Kan, via jouw promotieonderzoek ben ik 
in de benzo’s gerold. Bedankt voor je bijdrage als co-auteur in de latere stadia van het 
promotietraject.
Nog niet genoemd, maar grote dank is verschuldigd aan alle patiënten, huisartsen, 
psychologen en interviewers zonder wie de uitvoering en afronding van het Benzoredux-
project en daarmee van dit promotie-onderzoek niet mogelijk zou zijn geweest.
Speciale bedankjes gaan uit naar vrienden en vriendinnen die al die jaren trouw bleven 
informeren naar de stand van zaken rond mijn proefschrift en mijn ontwijkende 
antwoorden steeds voor lief namen; ook bedankt voor alle gezellige afleiding! Jeremy, 
zonder jou had dit boekje er niet zo mooi uitgezien. Mijn oud-collega’s Annemarie, 
Jeanneke en Mariëlle wil ik noemen, omdat zij het hele proces vanaf het begin hebben 
meegemaakt en ik met hen lief en leed heb kunnen delen, ook op andere gebieden. Wanneer 
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gaan we weer een hapje eten? Ook mijn huidige collega’s van Centrum Autisme noem ik 
vanwege hun interesse en aanmoedigingen en de last-minute correcties (Ankie en Ben, 
much obliged!). Interimteamleider Ary gaf me de mogelijkheid meer tijd in mijn onderzoek 
te steken. Misschien was het anders nog steeds niet af geweest. 
Voor mijn ouders, broer en schoonouders: bedankt voor alle harten onder de riem. 
Het is gelukt!
En tot slot, Ilco, mijn steun in de rug, degene die alles weer in het juiste perspectief kon 
brengen en die me streng toesprak als ik weer eens aan het uitstellen was. Dank je wel!
Het zit erop!
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